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ABSTRACT 
 
 
 
PULMONARY DELIVERY OF ANORECTIC GUT SECRETED PEPTIDES FOR 
APPETITE SUPPRESSION IN RATS 
 
By Priya P. Nadkarni, M.S., B.Pharm. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2009 
 
Major Director:  Masahiro Sakagami, Ph.D. 
Assistant Professor 
Department of Pharmaceutics, School of Pharmacy 
 
 
 
 
This dissertation project aimed to demonstrate that pulmonary delivery of two 
anorectic gut secreted peptides, peptide YY (PYY) and oxyntomodulin (OXM) enabled 
food intake suppression and reduced body weight gain in rats via their systemic 
absorption from the lung and interaction with the brain. After PYY and OXM were 
administered to the lungs at varying doses, food intake and body weight gain were 
monitored in freely feeding rats. Significant 30-35 % food intake suppression was 
achieved for 4-6 h following pulmonary administration of endogenously active PYY3-36 
and OXM1-37 at 0.80 and 0.50 mg/kg, respectively. Moreover, when administered daily 
for 7 days, these peptides enabled significant reduction of body weight gain by 39.4 and 
  xxii 
62.3 %, respectively. However, neither of their active fragment peptides, PYY13-36, 
OXM30-37 and NAc-OXM30-37 was effective at doses equimolar to the effective doses of 
PYY3-36 and OXM1-37. For PYY3-36, its pulmonary administration caused c-Fos activation 
in the hypothalamus arcuate nucleus (ARC) only, which was concurrent to reduced 
orexigenic neuropeptide Y (NPY), suggesting its appetite suppression was mediated via 
the central nervous system (CNS). In contrast, OXM1-37 caused c-Fos activation in both 
the hypothalamus ARC and brainstem AP, which implied the involvement of the CNS 
control and vagal stimulation for this peptide. As it was clear that these effects resulted 
from their lung absorption and increased plasma levels, the pharmacokinetics of one of 
the peptides, PYY3-36 was characterized following pulmonary administration. The plasma 
profiles were dose-proportional and kinetically, non “flip-flop”, yielding the highest 
PYY3-36 concentrations (Cmax) of 75.0±9.3 and 726.3±69.0 ng/ml at 0.08 and 0.80 mg/kg, 
respectively, at 10 min. According to a new kinetic model developed in this project, the 
percent absolute bioavailability (% F) was estimated to be 12-14 %, as derived from the 
lung absorption (ka) and non-absorptive loss rate constant (knal) of 0.03 min-1 and 0.17-
0.22 min-1, respectively. Overall, this research provided the first proof-of-concept for 
effective appetite suppression with pulmonary delivery of anorectic gut secreted peptides 
via systemic absorption. 
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CHAPTER 1 
 
 
BACKGROUND AND SIGNIFICANCE 
 
 
OBESITY AND CURRENT TREATMENT 
 
 Obesity is a metabolic disorder, recognized as a serious global epidemic by the 
World Health Organization (WHO) in the developed and a part of the developing 
countries (WHO, 2005). Approximately 1.6 billion adults worldwide are classified as 
overweight, and at least 400 millions as obese, on the basis of the body mass index (BMI) 
criteria of  ≥ 25 and ≥ 30, respectively (WHO, 2005). In the United States (US), the 
National Health and Nutrition Examination Surveys (NHANES) reported > 65 % and 
35.3 % of the adult population as overweight and obese, respectively, and more seriously, 
16.3 % of the children and adolescent population as obese (NHANES, 2006). This 
metabolic disorder is a considerable concern, as it leads to an underlying risk factor for 
certain fatal morbidities and mortalities including coronary heart diseases, type 2 
diabetes, cancer, hypertension, dyslipidemia and stroke (WHO, 2006). As a result, 
obesity has been blamed to account for an economic burden of 92.6 billion dollars on the 
US national health expenditure in 2003 (Finkelstein et al., 2003). It is clear therefore, that 
this global epidemic should be controlled by any means, including effective 
pharmacotherapy, life-style modification and bariatric surgery. 
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 From a physiological perspective, obesity is a manifestation of energy imbalance 
between intake and expenditure (WHO, 2005). Hence, to restore this imbalance, it is 
logically obvious that energy intake should be decreased and/or energy expenditure 
should be increased. In this regard, energy intake has been suggested to be controlled by 
complex neuroendocrinological mechanisms of satiety and hunger, while energy 
expenditure is more closely associated with physical activity like exercise, also altered by 
physiological signals (Bray and Greenway, 2007). Therefore, in theory, it would be 
beneficial to induce satiety, decrease hunger and/or promote energy expenditure in order 
to manage or treat the energy imbalance in obesity. Table 1.1 lists pharmacological 
agents approved as weight loss drugs by the US Food and Drug Administration (FDA). 
Most drugs employ one or more of this paradigm as their mechanisms. Sympathomimetic 
agents and selective serotonin-norepinephrine reuptake inhibitors act in the central 
nervous system (CNS), modulating the release and/or uptake of neurotransmitters such as 
norepinephrine, serotonin and dopamine, all of which are shown to induce satiety and/or 
increase energy expenditure. In contrast, lipase inhibitors act locally in the 
gastrointestinal (GI) tract, inhibiting the gastric and pancreatic lipase enzymes for 
digestion and reducing absorption of dietary lipids and thus, energy intake (Bays, 2004; 
Bray and Greenway, 2007). As a result, these drugs successfully induce weight loss, yet 
only by ~10 % following long 6-24 months of chronic treatment. Moreover, their side-
effects are relatively serious, as described in Table 1.1, and discontinuation appears to 
cause weight gain rebound (Bray and Ryan, 2007). As a result, these drugs are not 
generally recommended in severe cases of obesity (e.g., subjects with a BMI > 50), 
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thereby leaving only a surgical option of gastric banding or bypass for 30-40 % weight 
loss, despite post-surgical complications and high operation costs (Suter et al., 2009). 
 
PHYSIOLOGICAL REGULATION OF APPETITE AND BODY WEIGHT  
Physiological control on satiety and hunger results in healthy appetite, leading to 
the maintenance of normal body weight. Such appetite regulation is complex and 
believed to be controlled by several endocrine signals for short-term appetite and 
long-term adiposity (Stanley et al., 2005). Among them, the short-term appetite signals 
are primarily secreted from different sites of the GI tract in the form of peptide hormones 
alongside local mechanical factors e.g., gastric distension (Cummings and Overduin, 
2007; Wren and Bloom, 2007). These gut secreted peptides are either orexigenic or 
anorectic in nature, regulating preprandial hunger and postprandial satiety, respectively 
(Bays, 2004; Wren and Bloom, 2007). In contrast, the long-term adiposity signals are 
secreted from the pancreas (e.g., amylin, insulin, pancreatic polypeptide and vasoactive 
inhibitory peptide; Gardiner et al., 2008) and the adipose tissue (e.g., leptin, adiponectin, 
apelin and desnutrin; Ahmadian et al., 2009, Stanley et al., 2005; Soriguer et al., 2009). 
These peptides have been suggested to regulate the metabolism of absorbed dietary 
nutrients and thus, the storage and use of energy in the form of adipose to maintain the 
body weight. Therefore, as the appetite control eventually leads to the adiposity and body 
weight regulation by the long-term signals, the short-term appetite regulating gut secreted 
peptides have been perceived as primary targets to restore the energy imbalance in 
obesity (Bays, 2004). 
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               Table 1.1 Pharmacological agents to produce weight loss, currently approved by the FDA.  
Adapted from Bray and Ryan, 2007; Howland, 2008; Rolls et al., 1998; Chanoine et al., 2005 
Class 
 
Drug Mechanism of 
action 
Weight loss Side-effects 
Dopamine- 
norepinephrine reuptake 
inhibitors  
 
Methamphetamine 
Mazindol 
Benzphatamine 
Diethylpropion 
Phendimetrazine 
Phenteramine 
Inhibition of 
norepinephrine 
and dopamine 
reuptake at nerve 
endings, inducing 
satiety 
 
10 % in 
9 months 
Tachycardia, 
hypertension and 
abuse potential 
Serotonin -
norepinephrine reuptake 
inhibitor 
 
Sibutramine 
 
Inhibition of 
norepinephrine 
and serotonin 
reuptake at nerve 
endings, inducing 
satiety and 
promoting energy 
expenditure  
 
8-10 % in  
6-24 months 
 
Increases heart rate 
and hypertension 
 
 
Lipase inhibitor 
 
Orlistat Inhibition of  
lipase enzyme, 
interfering in 
absorption of 
dietary lipids 
  
> 8 % in  
 6 months 
Diarrhea, 
fecal urgency and 
abdominal pain 
4
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GUT SECRETED PEPTIDES FOR APPETITE REGULATION 
            Figure 1.1 shows such gut secreted peptides currently known to control appetite in 
human. Ghrelin is the only orexigenic peptide, secreted preprandially from the oxyntic 
cells lining the stomach. In contrast, cholecystokinin (CCK), glucagon like peptide-1 
(GLP-1), oxyntomodulin (OXM) and peptide YY (PYY) are the anorectic peptides, 
secreted postprandially from the distal parts of the intestine and colon (Wren and Bloom, 
2007; Cummings and Overduin, 2007).  
 
                                       
 
 
 
 
 
 
 
 
 
Figure 1.1 Gut secreted peptides known to control appetite in human. 
 
In obesity, the postprandial blood levels of some of the anorectic gut secreted 
peptides have been shown to be considerably low, while the ghrelin levels appear to be 
Ghrelin 
CCK 
GLP-1 
OXM 
PYY 
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elevated, compared to those in lean subjects, resulting in delayed onset of satiety 
(Batterham et al., 2003; Cohen et al., 2003; le Roux et al., 2006). For instance, in obese 
and lean subjects, the endogenous postprandial levels of ghrelin were 108.4 and 78.2 pM, 
and those of PYY were 14.4 and 23.5 pM, respectively (Batterham et al., 2003; le Roux 
et al., 2006) In fact, certain genetic cases of obesity are associated with either complete 
deficiency of anorectic peptides or their release (Goldstone, 2006). Therefore, restoring 
these peptides by exogenous administration has gained tremendous attention as a logical 
and promising concept for obesity management and treatment. As a result, several pre-
clinical and clinical attempts have been made in recent years to assess their feasibility of 
food intake or appetite suppression and/or reduction of body weight (gain) in the long-
term, primarily via parenteral injections. CCK and GLP-1 were tested as the first 
anorectic candidates, but their rapid enzymatic degradation and extremely short half-life 
(e.g., ~2 min) resulted in only marginal effects (Crawley and Beinfeld, 1983; Orskov et 
al., 1993). PYY and OXM have been then studied extensively, which have indeed 
provided promising results, leading to their potential use in obesity, as described below 
(Batterham et al., 2002; Dakin et al., 2002). 
 
PEPTIDE TYROSINE-TYROSINE (PYY) 
Peptide tyrosine-tyrosine (PYY1-36) is an endogenous 36-amino acid peptide with 
a molecular weight of 4310 Da, generated enzymatically from its precursor, propeptide 
YY in the enteroendocrine L cells of the intestinal mucosa, particularly lining the ileum 
and colon (le Roux and Bloom, 2005). It is secreted postprandially in proportion to 
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calorie intake (Ballantyne, 2006; Karra et al., 2009; le Roux and Bloom, 2005). The 
amino acid sequences of human (h) and rat (r) PYYs are shown in Figure 1.2.  
 
Figure 1.2 Amino acid sequences of human (h) and rat (r) peptide YY (PYY). Two 
amino acids at position 3 and 18 indicated by arrows are different between 
the species. Dipeptidyl peptidase IV (DPPIV) cleaves the peptide between 
position 2 and 3 (dotted line), producing PYY3-36. 
 
In humans, under the fasting state, the systemic level of PYY remains low at 12 pM 
(0.05 ng/ml; Grandt et al., 1994). In response to meal intake, however, the level increases 
and then reaches its peak at 49 pM (0.2 ng/ml) within 60 min, while remaining elevated 
for 6 h (Batterham et al., 2003; Grandt et al., 1994). Likewise, in rodents, the post-
prandial level of PYY has been reported to be 56.6-160.0 pM (0.23-0.65 ng/ml; le Roux 
et al., 2006; Jin et al., 1993). Notably, this PYY1-36 is cleaved by dipeptidyl peptidase IV 
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(DPPIV) during and/or following secretion, producing its N-terminus truncated, 
34-amino acid peptide, PYY3-36 (Ballantyne, 2006; Karra et al., 2009; le Roux and 
Bloom, 2005). Therefore, the systemic levels are comprised of both PYY1-36 and PYY3-36, 
and their postprandial proportions were reported to be ~36 and ~64 %, respectively 
(Grandt et al., 1994). As is the case with most of the gut secreted peptides, this circulating 
PYY is believed to gain access to the brain, thereby exerting its effect through interaction 
with the presynaptic neuropeptide Y (NPY) family receptors (Karra et al., 2009; le Roux 
and Bloom, 2005). Table 1.2 summarizes the inhibitory binding affinities of PYY1-36 and 
PYY3-36 to various rat NPY receptor subtypes against 125I-PYY (Nygaard et al., 2006). 
While PYY1-36 was shown to bind the Y1-, Y2- and Y5-receptor subtypes, PYY3-36 
exhibited the highest affinity to the Y2-receptor subtype (Wyss et al., 1998; Nygaard et 
al., 2006). This suggested that the N-terminus of PYY1-36 enabled interaction with the 
Y1- and Y5-receptors, but was not so critical for the Y2-receptor binding (Keire et al., 
2000; Nygaard et al., 2006). Quite interestingly, the binding of PYY to the Y1- and Y5- 
receptors appears to stimulate appetite, whereas the binding to the Y2-receptors 
suppresses appetite (Batterham et al., 2002; Chelikani et al., 2005). 
Table 1.2 The half-maximal inhibitory concentrations (IC50) of PYY1-36, 
PYY3-36 and PYY13-36 to different rat NPY receptor subtypes;  
Adapted from Westfall et al., 2006; Wyss et al., 1998. 
Peptide (IC50 nM) 
Y1               Y2                Y4                Y5 
  
1PYY1-36  2.36              0.22             47.58             0.45 
   1PYY3-36 45.24             0.25        > 277.83             1.17 
  
2PYY13-36                     15.0 
1Inhibitory activity against 125I-PYY using cell membranes stably 
transfected with each of the rat NPY receptor subtypes 
2Inhibitory effect on the electrically-induced increase in catecholamine 
synthesis from the perfused mesenteric arterial bed 
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Correspondingly, in rodents, intracerebroventricular injection of PYY1-36 was shown to 
induce food intake and body weight gain, whereas that of PYY3-36 resulted in their 
suppression (Boggiano et al., 2005). Moreover, food intake suppression caused by 
PYY3-36 was absent in the Y2-receptor knockout mice (Batterham et al., 2002) as well as 
in normal rats with the Y2-receptor antagonism, both of which were in line with the 
involvement of the Y2-receptors in the food intake suppression of PYY3-36 (Abbott et al., 
2005; Talsania et al., 2005). In contrast, intravenous infusion of PYY1-36 in rats was 
shown to be 10-times less potent in food intake suppression than PYY3-36 (Chelikani et 
al., 2005). This was presumably due to its binding to the Y1-and Y5-receptors which 
counteracted the suppressive effect mediated through the Y2-receptors. In fact, when 
subcutaneous injection was employed for PYY1-36, the food intake suppression was 
shown to be as potent as that for PYY3-36, presumably by virtue of its efficient conversion 
to PYY3-36 (Unmiappan et al., 2006). Meanwhile, various analogs of PYY such as 
PYY13-36, PYY22-36, PYY25-36 and their acetylated forms, Ac-PYY22-36 and Ac-PYY25-36 
have been tested in vitro, with respect to their NPY receptor binding activities to identify 
the most active moiety for food intake suppression (DeCarr et al., 2006). Among them, 
the C-terminal fragment, PYY13-36 has been shown to be “active” in the Y2-receptor 
related activities, i.e., NPY binding displacement in the rat brain (Walker and Miller, 
1988) and inhibition of catecholamine synthesis in the rat mesenteric bed (Westfall et al., 
2006). Even so, its in vitro molar potency was reported to be less than a half of that for 
the full length PYY (Wahlestedt et al., 1986; Walker and Miller, 1988; Westfall et al., 
2006). Therefore, such fragment peptides could be effective in the food intake 
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suppression if they attain considerably high concentrations in the systemic circulation as 
a result of higher absorption by virtue of lower molecular weights than PYY3-36. Such a 
hypothesis has yet to be tested for appetite suppression. 
Based on this selectivity and high affinity to the Y2-receptors, the endogenously 
active metabolite, PYY3-36 has been pursued in pre-clinical and clinical studies in order to 
assess its potential to cause appetite suppression and reduced body weight (gain), yet 
primarily following injections. Table 1.3 summarizes such studies for PYY3-36 published 
in the literature. Across the species, its parenteral injections demonstrated significant 
food or calorie intake suppression by 30-35 % in most studies. As a result, its repeated 
injections and subcutaneous infusions for 7-28 days enabled reduced body weight gain by 
20 % in various animal models of diet induced-or genetic-obesity (Batterham et al, 2002; 
Pittner et al., 2004; Tschöp et al., 2004; Vrang et al., 2006). Indeed, these effects were 
also shown to be accompanied with increased energy expenditure and altered substrate 
partitioning towards fat oxidation, both of which favorably reduced body weight gain 
(Pittner et al., 2004; Vrang et al., 2006). However, the effect on body weight with 
repeated administration of PYY3-36 has so far been transient due to unknown 
pharmacological mechanisms (Batterham et al, 2002; Pittner et al., 2004; Tschöp et al., 
2004; Vrang et al., 2006). In humans, while peripheral injections of PYY3-36 similarly 
caused promising appetite suppression, its effects on the body weight in the long-term 
have yet to be demonstrated.  
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Table 1.3 Food or calorie intake studies following PYY3-36 administration in various               
species in the literature. 
Species Route Dose 
(mg/kg) 
Dosing  Maximum % 
food/caloric 
intake 
suppression 
Reference 
Mouse IP 0.02 Single 33 Adams et al., 2004 
Mouse IP 0.10 Single 50 Challis et al., 2003 
Mouse IP 0.10 Single 40 Halatchev et al., 2004 
Mouse IP 1.20 Single 30 Neary et al., 2005 
Mouse IP 0.09 Single 38 Parkinson et al., 2008 
Mouse SC 0.80 Single 50 Shechter et al., 2005 
Mouse IP 1.00 Single 36 Vrang et al., 2006 
Rat IP 0.10 Single 36 Batterham et al., 2002 
Rat IP 0.05 x 2 7 days 10 Batterham et al., 2002 
Rat SC 0.10 28 days 6 Pittner et al., 2004 
Rat SC 1.00 7 days 30 Tschop et al., 2004 
Rat IP 0.03 Single 29 Abbott et al., 2005 
Rat IV (3 h) 0.01 Single 47 Chelikani et al., 2005 
Human IV (1.5 h) 0.0003 Single 36 Batterham et al., 2002 
Human IV (1.5 h) 0.0002 Single 34 Batterham et al., 2003 
Human IV (1 h) 0.0002 Single 32 Degen et al., 2005 
IP = intraperitoneal injection, SC = subcutaneous infusion with osmotic pump and IV = intravenous bolus 
injection or infusion 
 
OXYNTOMODULIN (OXM) 
Oxyntomodulin (OXM1-37) is an endogenous 37-amino acid peptide with a 
molecular weight of 4425 Da and co-secreted with PYY from the enteroendocrine          
L-cells of the ileum and colon (Dakin et al., 2001; Dakin et al., 2004). The amino acid 
sequence of OXM is shown in Figure 1.3. OXM is one of the peptides, enzymatically 
produced from the propeptide precursor, enteroglucagon, and released postprandially in 
proportion to meal intake (Ghatei et al., 1983). Under the fasting state in humans, the 
systemic level of OXM remains low at 50 pM (0.2 ng/ml; Cohen et al., 2003). However, 
in response to meal intake, its post-prandial level reaches its peak at 150 pM (0.7 ng/ml) 
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Figure 1.3 Amino acid sequence of oxyntomodulin. 
 
within 60 min, while remaining elevated for several hours (Cohen et al., 2003; Ghatei et 
al., 1983; Hornnes et al., 1980). This peptide has been shown to be metabolized by 
dipeptidyl peptidase IV (DPPIV) and neutral endopeptidase (NEP), thereby speculating  
quite a short half-life in the blood circulation (Druce et al., 2009). Like PYY, OXM1-37 is 
secreted into the systemic circulation to interact with the brain directly or into the GI 
interstitial fluid to activate nearby vagal fibers to exert the local effects such as inhibition 
of gastric acid secretion and delay of gastric emptying (Dakin et al., 2004).  
Central and peripheral injections of OXM1-37 demonstrated significant food intake 
suppression as well as long-term effects on body weight in rodents and humans (Dakin et 
al., 2001; Dakin et al., 2002; Dakin et al., 2004; White et al., 2008; Wynne et al., 2006). 
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Table 1.4 summarizes such studies in rodents and humans published in the literature. 
Intraperitoneal and intracerebroventricular injections demonstrated dose-proportional and 
relatively sustained food intake suppression by 28-50 % for 8-12 h in rats (Dakin et al., 
2001; Dakin et al., 2002; Dakin et al., 2004). Moreover, these routes of administration 
were shown to promote satiety by other mechanisms including local effects of reduced 
gastric acid secretion, delayed gastric emptying and gastrointestinal transit as well as 
reduced circulating levels of the orexigenic gut peptide, ghrelin (Dakin et al., 2004). 
When injected repeatedly for 7 days, OXM1-37 demonstrated ~10 and ~44 % food intake 
suppression and reduced body weight gain, respectively, at the end of the study (Dakin et 
al., 2002; Dakin et al., 2004). This effect on the body weight was believed to be 
associated, at least in part, with increased energy expenditure, in addition to food intake 
suppression. In humans, intravenous infusion and subcutaneous injections of OXM1-37 
resulted in reduced calorie intake by 17-35 % (Wynne et al., 2005; Wynne et al., 2006). 
As a result, repeated subcutaneous injections for 4-28 days in obese and overweight 
subjects enabled significant increase in energy expenditure by 29 % and reduction of the 
body weight by 2.3 kg, in addition to reduction of the energy intake (Wynne et al., 2005; 
Wynne et al., 2006).  
While being subject of further verification, this appetite suppression by OXM1-37 
is believed to be mediated by the GLP-1 receptors (Baggio et al., 2004; Druce et al., 
2009). Indeed, OXM1-37 exhibited a fairly potent in vitro affinity to the GLP-1 receptors 
(IC50 = 33.1 nM; 146.5 ng/ml), although approximately 100-fold lower than GLP-1 (IC50 
= 0.34 nM; 1.5 ng/ml; Druce et al., 2009). However, the food intake suppression by 
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OXM1-37 was only partially blocked by the GLP-1 receptor antagonism using exendin-9 
in rats (Baggio et al., 2004). Moreover, its intraperitoneal injection in the GLP-1 receptor 
knock-out mice failed to cause food intake suppression (Baggio et al., 2004). Hence the 
exact mechanisms involved in the biological activity of OXM are yet to be verified. 
 
Table 1.4 Food or calorie intake studies following OXM1-37 administration in various 
species in the literature. 
Species Route Dose    
(mg/kg) 
Dosing  Maximum % 
food/caloric 
intake 
suppression 
Reference 
Mouse ICV 0.004 Single 70 Baggio et al., 2004 
Mouse IP 4.0 Single 60 Chaudhri et al., 2006 
Mouse IP 12.0 Single 60 Druce et al., 2009 
Mouse IP 6.2 Single 20 Parkinson et al., 2008 
Mouse IP 6.2 Single 28 White et al., 2008 
Rat ICV 0.04 Single 50 Dakin et al ., 2001 
Rat IP 0.4 Single 30 Dakin et al ., 2004 
Rat ICV 0.01 x 2 7 days 10 Dakin et al ., 2002 
Rat IP 0.2 x 2 7 days 12 Dakin et al ., 2004 
Human IV (1.5 h) 0.008 Single 19 Cohen at al., 2003 
Human* SC 0.02 x 3 4 days 17 Wynne et al., 2006 
Human* SC 0.02 x 3 28 days 35 Wynne et al., 2005 
ICV= intracerebroventricular injection, IP = intraperitoneal injection, SC = subcutaneous infusion with 
osmotic pumps and IV = intravenous infusion. * indicate studies in overweight and obese subjects 
receiving self-subcutaneous injection at 0.02 mg/kg at 30 min prior to each meal intake for 4 and 28 days, 
respectively. 
 
Like PYY, various low molecular weight active fragments of OXM have been 
tested for in vitro receptor binding affinity (Druce et al., 2009). The C-terminal 
octapeptide, OXM30-37 appeared to be the minimally required fragment for the activity, 
e.g., inhibition of gastric acid secretion in various rodent models (Carles-Bonnet et al., 
1991; Jarrousse et al., 1985; Jarrousse et al., 1986). However, it was in 2009 that its in 
vitro GLP-1 receptor binding affinity was finally determined, reporting an IC50 
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>10,000 nM (Druce et al., 2009), indicating almost negligible receptor binding affinity, 
despite its ~150-fold less in vivo molar potency than the full length peptide, OXM1-37 
(Carles-Bonnet et al., 1991; Jarrousse et al., 1985; Jarrousse et al., 1986). Because this 
was likely attributed to its rapid metabolic degradation, its N-terminal acetylation was 
shown to be successful in increasing the potency by 3-fold, compared to OXM30-37, by 
virtue of metabolic protection. Unfortunately however, this potency was still 30-fold less 
than OXM1-37 (Carles-Bonnet et al., 1991; Carles-Bonnet et al 1992; Jarrousse et al., 
1985; Jarrousse et al., 1986), unless a ~4-fold lower molecular weight of OXM30-37 would 
be greatly beneficial in absorption. Consistent with these receptor affinity data, it was 
again in 2009 that intraperitoneal injection of OXM30-37 was shown to be ineffective in 
causing food intake suppression (Druce et al., 2009). 
 
APPETITE REGULATION BY GUT SECRETED PEPTIDES VIA THE BRAIN 
Following secretion into the systemic circulation, the gut secreted peptides are 
believed to access the appetite regulating centers in the brain, the hypothalamus and the 
brainstem, through the poorly formed blood-brain-barrier (Wren and Bloom, 2007). 
Figure 1.4 is a schematic representation of such interactions of the gut secreted peptides 
with the appetite regulating centers in the brain, involving neuroendocrinological signals. 
In the hypothalamus, the arcuate nucleus (ARC) region is considered to be critical in the 
appetite control, by virtue of secretion of orexigenic neurpeptide Y (NPY) and anorectic 
α-melanocyte stimulating hormone (α-MSH; Wren and Bloom, 2007). These two 
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opposing neuronal peptide signals are believed to be well coordinated to control appetite 
and thus, regulate body weight (Gardiner et al., 2008).  
 
 
Figure 1.4 Neuroendocrinological pathways involved in appetite regulation. 
                             Adapted from Druce et al., 2004 
 
Indeed, most of the gut secreted peptides have been shown to modulate NPY and/or 
α-MSH secretion via their direct interactions with specific receptors located on the nerve 
endings of the primary neurons in this ARC region (Gardiner et al., 2008; Schwartz et al., 
2000). Subsequently, it is believed that such primary neuronal nerve endings project into 
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the secondary appetite regulating brain center, the hypothalamus paraventricular nucleus 
(PVN), followed by integration of the appetite signals in the higher cortical brain centers 
(Gardiner et al., 2008; Schwartz et al., 2000). Meanwhile, in the brainstem, the nucleus of 
solitary tract and area postrema (AP) regions are considered to be vital components of the 
parasympathetic vagal afferent system for appetite control. It is believed that the gut 
secreted peptides exert local GI effects, e.g., altered gastric acid secretion and delayed 
gastric emptying, through receptor interactions on the vagal afferent nerve endings. These 
peripheral signals are then transmitted by the vagal afferents to the neurons in the 
brainstem region for their integration in the hypothalamus and higher cortical regions 
(Cummings and Overduin, 2007; Hameed et al., 2009).  
The signal transduction cascades for these gut secreted peptides are known to 
involve neuronal activation, often represented by the c-Fos protein from the Fos family 
that regulates certain neuropeptide genes, including those involved in the appetite control, 
such as NPY. c-Fos is a 55 kDa protein, typically activated within neuronal cells of the 
neuroendocrine system, in response to certain stimuli, such as the gut secreted peptides 
(Batterham et al., 2002; Dakin et al., 2004; Hoffman et al., 1993; Rowland et al., 1997). 
Subsequently, this protein undergoes heterodimerization with the Jun family protein, 
c-Jun, and forms the transcription factor, activation protein-1 (AP-1). The binding of this 
AP-1 to the regulatory region of the target neuroendocrine genes, such as NPY, is known 
to alter their expressions, either in an activated or suppressive manner. Normally, the c-
Fos expression remains low in various brain regions (Hughes et al., 1992). However, in 
response to acute and chronic challenges by certain endocrine hormones like gut secreted 
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peptides, the c-Fos protein expression was shown to reach maximum between 1-3 h and 
remain detectable for 6 h within the cell nucleus (Hoffman et al., 1993; Kovacs, 1998). 
Therefore, this c-Fos expression has been often assessed as a non-specific neuroendocrine 
marker to identify the target activated brain locations, associated with the actions and 
mechanisms of the gut secreted peptides. 
APPETITE SUPPRESSION BY PYY AND OXM VIA THE BRAIN  
Appetite suppression by PYY3-36 appears to result from its action in the brain 
(Batterham et al., 2002). Parenteral injections in rodents considerably increased the c-Fos 
expression in the hypothalamus ARC region, likely associated with its Y2-receptor 
interaction for food intake suppression (Batterham et al., 2002; Halatchev et al., 2004; 
Koda et al., 2005; Neary et al., 2005). Consistently, intraperitoneal injection in mice 
significantly reduced the orexigenic NPY mRNA expression in the hypothalamus ARC 
region (Batterham et al., 2002; Challis et al., 2003; Parkinson et al., 2008). In contrast, 
however, peripheral injections were shown to increase c-Fos expression in the brainstem 
AP region, a component of the dorsal vagal afferent system (Abbott et al., 2005; Koda et 
al., 2005; le Roux and Bloom, 2005). The Y2-receptors are indeed located on the nodose 
ganglion and vagal afferents, thereby suggesting the possible binding of peripherally 
injected PYY3-36 with these receptors for increased vagal afferent firing and thus, exerting 
local actions on delayed GI emptying and prolonged intestinal transit time (Abbott et al., 
2005; Berthoud and Morrison 2008; Dumont et al., 2007; Karra et al., 2009; Koda et al., 
2005; le Roux and Bloom, 2005). On the contrary, despite the absence of an intact vagal 
afferent system, peripheral injection of PYY3-36 continued to cause food intake 
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suppression in vagotomized rats (Cox and Randich, 2004; Halatchev and Cone, 2005). 
Therefore, the role of the vagal pathway in the food intake suppression by PYY3-36 has so 
far been mixed, requiring further clarification. 
Peripheral injections of OXM1-37 were also shown to increase c-Fos expression in 
the hypothalamus ARC region and thus, its food intake suppression was believed to result 
from interaction in the CNS (Chaudhri et al., 2008; Dakin et al., 2004). Meanwhile, the 
increased c-Fos activation in the hypothalamus PVN and brainstem AP regions has been 
shown inconsistently. As a result, the involvement of the secondary appetite regulating 
center and vagal afferent pathway, respectively, remains inconclusive for this peptide 
(Chaudhri et al., 2006; Dakin et al., 2001; Dakin et al., 2004). This was further 
confounded by the fact that direct injection of OXM1-37 into the hypothalamus PVN 
region exhibited food intake suppression (Dakin et al., 2001). Therefore, the exact brain 
mechanisms for OXM1-37 induced appetite suppression have not yet been resolved, except 
for the concurrent increase in the release of an anorectic neuropeptide, α-MSH (Dakin et 
al., 2004) and the likely involvement of the GLP-1 receptors (Baggio et al., 2004; Dakin 
et al., 2004). 
 
ANORECTIC GUT SECRETED PEPTIDES AND EFFECTS IN ANIMALS  
As shown in Tables 1.3 and 1.4, food intake suppression and reduced body weight 
gain have been consistently demonstrated in rodents following exogenous administration 
of PYY3-36 and OXM1-37. Indeed, while these studies were carried out in different animal 
models (e.g., lean, diet-induced, genetic- or diabetic-obese animals) under different 
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conditions (e.g., fed or fasting protocol, dosing regimen and route of administration), 
clear differences in the food intake suppression by PYY3-36 and OXM1-37 were shown 
between species (Batterham et al., 2003; Dakin et al., 2004; Halatchev et al., 2004; Neary 
et al., 2005; Pittner et al., 2004). For instance, for OXM1-37, the minimum effective dose 
in rats was ~10 fold lower than in mice, yet showing comparable magnitude of food 
intake suppression (Baggio et al., 2004; Neary et al., 2005; Dakin et al., 2004). This may 
have an implication to different brain locations involved for OXM1-37 between species, 
while depending also on its routes of administration (Baggio et al., 2004; Challis et al., 
2003; Chaudhri et al., 2006; Dakin et al., 2004). Likewise, for PYY3-36, the effective dose 
of subcutaneous infusion appears to be higher in the obesity model than the lean 
counterpart, likely due to differences in the metabolism and adiposity (Pittner et al., 
2004). Notably, the doses of PYY3-36 and OXM1-37 shown to be effective in these rodents 
were ~10-30-fold higher than those necessary in humans (Batterham et al., 2003; Cohen 
et al., 2003; Degen et al., 2005; Wynne et al., 2005).  
 
PULMONARY DELIVERY OF ANORECTIC GUT SECRETED PEPTIDES 
From a drug delivery perspective, parenteral injections have been a logical choice 
for these anorectic gut peptides, because of their macromolecular peptide nature (~4 kDa 
of molecular weight) and likely susceptibility to enzymatic degradation, which would 
preclude most of their epithelial absorption (e.g., from the GI tract following oral 
administration; Scheuch et al., 2006). Indeed, as summarized in the Tables 1.3 and 1.4, 
the effective routes of administration for PYY3-36 and OXM1-37 have been confined to 
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injections (e.g., intravenous, intraperitoneal or subcutaneous injection or infusion) only, 
in order to cause significant food intake or appetite suppression in animals and humans. 
However, it is clear that non-parenteral and needle-free administration would be highly 
desirable for these anorectic peptides, given a likely need of repeated administration on a 
daily basis for appetite control. Accordingly, for PYY3-36, attempts have been made as a 
nasal spray with a tight junction modulator (Gantz et al., 2007) and an oral formulation 
with a proprietary small organic “carrier” (Beglinger et al., 2008). Both formulations 
were shown to achieve the effective systemic PYY concentrations with the help of the 
enhancers. However, the food intake suppression and long-term body weight reduction 
were only achieved, when the subjects were not tolerated to the peptide administration, 
exhibiting adverse effects of nausea, vomiting and abdominal discomfort (Gantz et al., 
2007; Beglinger et al., 2008).  
In this context, it has been often suggested that the lung offers favorable features 
for systemic absorption of macromolecules, such as a large surface area of near 100 m2, 
thin alveolar epithelium ≤ 0.5 µm, rich blood supply equivalent to cardiac output, and 
lesser peptidase activity (Patton., 1999; Patton et al., 2004; Patton and Byron, 2007). 
Indeed, inhaled insulin demonstrated successful postprandial glycemic control in diabetes 
mellitus, as a result of its absorption from the lung (Khafagy et al., 2007) that was shown 
to cause faster onset of action, compared to subcutaneous injection (Heinemann et al., 
1997; Owens et al., 2003). Therefore, it may be more rationalized to exploit the lung as a 
needle-free portal for systemic delivery of these anorectic gut secreted peptides, without 
the use of absorption enhancers. 
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Accordingly, this project was designed to demonstrate a proof-of-concept that the 
lung can be exploited as a portal for delivering the anorectic gut secreted peptides, PYY 
and OXM, to the systemic circulation and then, to the brain, sufficient to exert appetite 
suppression and/or reduced body weight gain. Using freely feeding rats as a model, an 
experimental setup and method to assess such behavioral changes by the peptide 
administration to the lung were first developed. The pharmacodynamics of food intake 
and body weight gain was then studied following pulmonary administration of PYY and 
OXM and their “active” analog peptides, in order to determine their dose-responses and 
molar potencies. These were supported by the immunofluorescence microscopic 
assessment for neuronal activation of the c-Fos protein in different regions of the brain. 
For PYY, reduced expression of the orexigenic NPY peptide in the brain was also sought, 
while its in vivo pharmacokinetics was characterized with respect to the systemic peptide 
levels, residence and bioavailability as well as the kinetics of lung absorption and 
disposition, using a new kinetic modeling approach.  
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CHAPTER 2 
 
HYPOTHESES 
 
 
This dissertation project hypothesized that pulmonary administration of anorectic 
gut secreted peptides caused significant food intake suppression, leading to reduced body 
weight gain in freely feeding rats, as a result of their systemic absorption through the lung 
and interaction with the appetite regulating center of the brain. The project first focused 
on the pharmacological assessment of two anorectic gut peptides, peptide YY (PYY) and 
oxyntomodulin (OXM), and their active fragment peptides with respect to their effect on 
food intake and body weight gain following pulmonary administration. This was further 
confirmed by clarifying their target locations within the brain through the 
immunofluorescent histological assessment of neuronal activation of c-Fos protein and/or 
reduced orexigenic neuropeptide Y (NPY). The project then proceeded to determine the 
kinetics of lung absorption and disposition for one of the promising peptides, PYY3-36, 
following pulmonary administration in rats, using a novel lung kinetic modeling 
approach. Overall, the project was designed to test the following six hypotheses: 
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1. Food and water intake and body weight gain will be monitored in rats in a 
physiological manner by minimizing the impact from anesthesia and surgical incision 
for pulmonary administration.  
 
2. Food intake suppression will be assessed following single pulmonary administration of 
PYY, OXM and their active fragment peptides in rats, with respect to their potency 
and duration. 
 
3. Repeated pulmonary administration of such potent anorectic peptides will cause 
reduced body weight gain in rats, as a result of continued and consistent food intake 
suppression. 
 
4. Pulmonary administration of PYY will cause the neuronal activation of c-Fos protein 
and the reduced NPY protein in the brain hypothalamus, concurrent to the food intake 
suppression.  
 
5. Pulmonary administration of OXM will cause the neuronal activation of c-Fos protein 
in the hypothalamus and brainstem, concurrent to the food intake suppression.  
 
6. Plasma concentration-time profiles of PYY3-36 following pulmonary administration 
will be accurately and precisely determined to clarify its kinetics of lung absorption 
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and disposition, compared to those for other 4-6 kDa peptides in the literature, using a 
novel lung kinetic modeling approach. 
In Chapter 3, PYY and its active fragment peptides were tested for the hypotheses 
1 through 4, following establishment of the physiological food intake and body weight 
monitoring system and minimally invasive pulmonary administration techniques. The 
food intake suppression and reduced body weight gain as well as neuronal activation and 
NPY reduction at different brain locations were studied following pulmonary 
administration. In Chapter 4, OXM and its active fragment peptides were tested for the 
hypotheses 2, 3 and 5. The food intake suppression and reduced body weight gain as well 
as neuronal activation at different brain locations were assessed following pulmonary 
administration. Finally, in Chapter 5, a novel kinetic modeling approach was employed to 
test the hypothesis 6 by determining and analyzing the plasma concentration-time profiles 
following pulmonary administration in rats. The kinetics of lung absorption and 
disposition for PYY3-36 were characterized and compared to those for other similar-sized 
peptides (4-6 kDa) in the literature. Finally, Chapter 6 summarized this dissertation 
project and provided general conclusions.  
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CHAPTER 3 
 
 
PULMONARY DELIVERY OF PEPTIDE YY (PYY) FOR 
FOOD INTAKE SUPPRESSION AND REDUCED BODY 
WEIGHT GAIN IN RATS     
 
3.A INTRODUCTION 
 
Anorectic gut secreted peptides such as PYY have been recognized and studied as 
potential therapeutic candidate molecules in the obesity management by virtue of their 
physiological role in appetite and body weight control through the brain (Chaudhri et al., 
2008; le Roux and Bloom, 2005). For PYY, several studies have proven that exogenous 
administration via injection or infusion caused significant food intake suppression and 
reduction of body weight (gain) in both animals and humans (Batterham et al., 2002; 
Batterham et al., 2003; Chelikani et al., 2005; Chelikani et al., 2006; Degen et al., 2005; 
Moran et al., 2005; Pittner et al., 2004; Sloth et al., 2007; Roth et al., 2007; Unmiappan et 
al., 2006). Even so, the clinical development of this peptide would encounter the classical 
biopharmaceutical drug delivery challenge, as the high molecular weight (4.3 kDa) and 
likely susceptibility to enzymatic degradation (Patton and Byron, 2007) would preclude 
its epithelial absorption in most cases. Clearly, however, non-parenteral and needle-free 
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administration would be highly desirable for PYY, based on its likely need of repeated 
administration for appetite control on a daily basis. In fact, such an attempt was made for 
an endogenously active peptide, PYY3-36 formulated as a nasal spray with a tight junction 
modulator in clinical studies (Gantz et al., 2007). However, it may be more rationalized 
that the lung offers a better non-injection portal for PYY’s systemic delivery without the 
use of absorption enhancers, as has been the case of inhaled insulin for successful 
postprandial glycemic control in diabetes mellitus (Khafagy et al., 2007).  
Accordingly, this chapter was aimed to demonstrate that pulmonary delivery of 
PYY could suppress food intake and reduce body weight gain in freely feeding rats. The 
chapter is composed of 1) the establishment of food intake and body weight monitoring 
system following minimally invasive pulmonary administration of anorectic peptides, 2) 
the assessment of food intake suppression and reduced body weight gain following single 
and daily repeated pulmonary administration of PYY, and 3) the clarification of target 
locations within the brain for PYY administered to the lung via immunofluorescence 
microscopy for c-Fos neuronal activation and orexigenic NPY expression. 
3.B MATERIALS AND METHODS 
3.B.1 MATERIALS 
 
 Human PYY1-36 (PYY1-36; molecular weight of 4310 Da) and PYY3-36 (molecular 
weight of 4050 Da) were purchased from American Peptide Company, Inc. (Sunnyvale, 
CA), whereas rat PYY13-36 (PYY13-36; molecular weight of 3014 Da) was from Bachem 
Americas, Inc. (Torrance, CA). These were received as lyophilized powders, certified to 
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contain 82.8, 82.2 and 80.7 % of the peptide in weight with 95.2, 98.6 and > 90.0 % 
purity, respectively; these values were used to prepare PYY dosing solutions accurately 
from powder weights. Isoflurane (USP) and sodium pentobarbital (Nembutal® Sodium 
Solution; 50 mg/ml), respectively, were obtained from Webster Veterinary Supply, Inc. 
(Sterling, MA) and Ovation Pharmaceuticals, Inc. (Deerfield, IL). Paraformaldehyde (EM 
grade) and Tissue-Tek® OCT embedding medium were from Ted Pella, Inc. (Redding, 
CA). Rabbit anti-rat c-Fos and NPY antibodies were from Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA) and Bachem, respectively, while Cy2- and Cy3-labeled goat anti-
rabbit immunoglobulin G (IgG) antibodies and normal goat serum were from Jackson 
ImmunoResearch Laboratories, Inc. (West Grove, PA). Other general reagents including 
Triton-X 100, bovine serum albumin (BSA; fraction V) and Sudan Black B were from 
Sigma-Aldrich (St. Louis, MO). 
3.B.2 ANIMALS 
 
 This research adhered to the NIH Principles of Laboratory Animal Care (NIH 
publication # 85-23, revised in 1985), and its protocol was approved by the Institutional 
Animal Care and Use Committee at Virginia Commonwealth University (VCU; Protocol 
AM10331). Sprague-Dawley rats (male; specific-pathogen-free) weighing 250-275 g 
were purchased from Hilltop Lab Animals, Inc. (Scottdale, PA). Each animal was housed 
individually in a metabolic cage and acclimatized for 7 days in the accredited animal care 
facility under the tightly controlled conditions with respect to temperature (20-23 oC), 
relative humidity (40-70 %) and light-dark cycling (12-12 h; the light cycle occurred 
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between 6 am and 6 pm). Throughout experiments, the animals had free access to pre-
weighed standard rat diet (7012; Harlan Teklad, Boston, MA) and tap water, so that their 
daily intake was monitored via weight difference, as also was the case for daily body 
weight gain. As suggested in the literature (Abbott et al., 2006; Farley et al., 2003), this 
7-day acclimatization was shown to be essential for the animals to demonstrate the 
physiological values of daily food and water intake and body weight gain. These were 
ensured to be reproducible, 30.4±0.6 g, 30.5±0.3 g and 5.8±0.1 g (mean±SE; n=68), 
respectively, across the animals used in this study.  
3.B.3 INTRA- AND ORO-TRACHEAL PULMONARY INSTILLATION 
          Because rat lungs were not readily accessible for peptide administration, a short-
acting anesthesia of isoflurane was used for intra- and oro-tracheal instillation of PYY 
solutions. Following 7-day acclimatization, each rat was anesthetized in a chamber box 
(Appendix 1) with 4 % (v/v) isoflurane vapors generated from a vaporizer (Ohmeda Tech 
4 Surgivet®, Smiths Medical North America, Waukesha, WN) in 95 % oxygen and 5 % 
air carrier gas at 3.5 L/min. Sufficient depth of anesthesia was typically attained within 5 
min, ensured by the absence of corneal and pedal reflexes. For intratracheal instillation, 
each anesthetized animal was placed in a supine position on a surgical board inclined at 
30ο and maintained under the isoflurane anesthesia by nose-only exposure. The tracheal 
region was exposed, and 60 µl of saline or various PYY solutions was directly instilled 
into the lung through an incision made at the 4-5th cartilaginous rings; the needle tip was 
projected just before the tracheal bifurcation. The surgical incision was then sealed with 
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the Nexaband® surgical glue (Webster Veterinary Supply, Inc., Sterling, MA). For 
orotracheal instillation, each anesthetized animal was placed in a supine position on a 
surgical board inclined at 60ο under the heat lamp, and its tracheal lumen was visually 
confirmed through the oral cavity using a small animal fiber-optic laryngoscope (LS-1; 
PennCentury, Inc., Philadelphia, PA). Then, 100 µl of saline or various PYY solutions 
was directly instilled into the lung using a 8.5 cm PEEK extension tubing (O.D. 0.01 mm; 
Upchurch Scientific, Oak Harbor, WA) attached to a 1 ml syringe; the tubing was 
inserted 3 cm down within the tracheal lumen, such that the tip was positioned just before 
the tracheal bifurcation. When repeated administration was tested, this orotracheal 
instillation operation was carried out daily for 7 days.  
Following intra- or oro-tracheal instillation, the animals were held in an upright 
position for 1 min to avoid cough reflexes before returning to the cages. The entire 
instillation operation was typically completed within 6 min of the isoflurane anesthesia, 
after which the animals regained consciousness within 4 min. After ensuring complete 
recovery from the anesthesia, the animals were returned to the animal care facility within 
30 min of instillation where food/water intake and body weight gain were monitored. 
3.B.4 SUBCUTANEOUS INJECTION UNDER THE SHAM INTRATRACHEAL 
INSTILLATION OPERATION 
A group of animals received a subcutaneous injection of PYY immediately after 
the sham operation of intratracheal instillation described above in 3.B.3. Each animal was 
anesthetized and placed in the supine position. Following tracheal exposure, the syringe 
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needle was inserted between the tracheal cartilaginous rings and removed immediately 
for subsequently sealing the incision with the Nexaband® glue. Immediately, the animal 
received a subcutaneous injection of PYY solution in the fold of the neck skin. After 
ensuring complete recovery from the anesthesia, the animals were returned to the animal 
care facility where food/water intake and body weight gain were monitored. 
3.B.5  FOOD INTAKE AND BODY WEIGHT GAIN FOLLOWING SINGLE           
PULMONARY AND SUBCUTANEOUS ADMINISTRATION OF PYYs    
Rats were divided into 9 groups with n=5-12 to assess the effects of different 
doses, PYYs, dosing methods and routes on the food intake and/or body weight gain. 
Because of the nocturnal nature of the animals, PYY administration was carried out          
~1 h before the dark-cycle commenced, i.e., ~5 pm. The groups comprised of 
intratracheal instillation of 1) saline (n=12), 2-4) PYY3-36 at 0.08, 0.40 and 0.80 mg/kg 
(n=7-8), 5) PYY1-36 at 0.90 mg/kg (n=6) and 6) PYY13-36 at 0.60 mg/kg (n=7), orotracheal 
instillation of 7) saline (n=7) and 8) PYY3-36 at 0.80 mg/kg (n=7) and finally, 
9) subcutaneous injection of PYY3-36 at 0.80 mg/kg in the sham-operated animals (n=5). 
Cumulative food intake was assessed 2, 4, 6, 24 and 48 h post-instillation, determined by 
the weight difference from the pre-weighed diet placed at the time of administration. The 
daily water intake and body weight gain were also monitored for 48 h following 
administration. 
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3.B.6  FOOD INTAKE AND BODY WEIGHT GAIN FOLLOWING DAILY 
REPEATED PULMONARY ADMINISTRATION  
A total of 20 rats were used and divided into 3 groups with n=6-7. At ~1 h before 
the dark-cycle commenced, i.e., ~5 pm, the animals received daily orotracheal 
instillations of 1) saline (n=7) or 2-3) PYY3-36 at 0.08 (n=6) or 0.80 mg/kg (n=7) for 
7 days. Cumulative food and water intake and body weight gain were monitored daily 
(every 24 h) for 8 days post-first instillation. In addition, the food intake was also 
determined 2, 4 and 6 h post-instillation on day 1, 4 and 7, to assess the continuity and/or 
consistency of the food intake suppression. In some experiments, the animals received an 
8th orotracheal instillation of saline or PYY3-36 on day 8 in order to assess c-Fos 
expression in the brain, as described below. 
 
3.B.7   IMMUNOFLUORESCENT DETECTION OF c-FOS AND NPY IN THE RAT 
HYPOTHALAMUS AND BRAINSTEM  
Neuronal activation of c-Fos and reduced expression of orexigenic NPY protein 
by PYYs administered to the lung were assessed in different regions of the brain via 
immunofluorescence histochemical microscopy, obtained at 4 h following single 
intratracheal instillation or the 8th orotracheal instillation in the repeated daily dosing 
protocol. Rats were anesthetized with an intraperitoneal injection of 50 mg/kg sodium 
pentobarbital. After the blood removal from the tissue by saline perfusion, the brains 
were then fixed by transcardial perfusion of 4 % (w/v) paraformaldehyde in 0.1 M 
phosphate buffered saline (PBS; pH 7.4) at a flow rate of 25 ml/min for 20 min (Neary at 
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al., 2005). The animals were decapitated, and the midbrain (involving the hypothalamus) 
and the brainstem were removed and dissected using the optic chiasm and cerebellum, 
respectively, as landmarks. The dissected tissue blocks were further fixed for 1 h with 
4 % (w/v) paraformaldehyde in 0.1 M PBS under vacuum, followed by 48 h 
cryoprotection with 30 % sucrose in 0.2 M PBS. These were subsequently embedded in 
the Tissue Tek® OCT medium, snap frozen with dry ice and liquid N2, and finally stored 
at -70 oC until sectioning. Frozen 30 µm thick coronal sections of the rat midbrain and 
brainstem were prepared using a cryostat (Microm HM 550, Thermo Fisher Scientific, 
Waltham, MA) and placed on the Superfrost® slides (Fisher Scientific, Pittsburg, PA); 
these were air-dried and stored at -20 oC until immunofluorescent detection of c-Fos and 
NPY, described below.  
For immunofluorescence staining of c-Fos and NPY, the sections were selected to 
include the arcuate nucleus (ARC) and paraventricular nucleus (PVN) regions of the 
hypothalamus as well as the area postrema (AP) region of the brainstem, referenced to 
the rat brain atlas (Kruger et al., 1995). These sections were first allowed to equilibrate to 
the room temperature and outlined with a hydrophobic PAP® marker pen to retain applied 
solutions. The sections were processed to remove the embedding medium by dipping the 
slides in 0.2 M PBS for 5 min, followed by serial dehydration with 70, 95 and 
100 % (v/v) ethanol for 0.5, 0.5 and 1.0 min, respectively, and rehydration with 0.2 M 
PBS containing 0.5 % (v/v) Triton-X 100 (PBST). The potential non-specific binding 
sites on the tissue were blocked by incubation for 1 h at room temperature with a 
blocking solution, PBST containing 4 % (w/v) BSA, 5 % (w/v) dry non-fat milk and 
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10 % (v/v) normal goat serum. The blocking solution was then aspirated, and the sections 
were incubated overnight at 4 °C with rabbit anti-rat c-fos or NPY polyclonal antibody, 
diluted 1:100 or 1:200 in the blocking solution, respectively. The unbound antibody was 
removed by washing the sections 4 x with PBST for 5 min each, followed by a reaction 
for 1 h at room temperature with Cy3- or Cy2-labeled goat anti-rabbit IgG antibody, 
diluted 1:200 in the blocking solution. Following 4 x wash with PBST for 5 min each, to 
remove the unbound antibody, Sudan Black B counter stain was applied for 10 min, 
enabling not only morphological identification of the ARC, PVN and AP regions but also 
quenching the autofluorescence signal. Finally, the sections were cover-slipped with 
glycerol mounting medium. This procedure had been successfully validated by omitting 
the primary and/or secondary antibodies, as described in Appendix 2. 
The c-Fos and NPY immunofluorescence images were captured under the BX40 
fluorescence microscope (Olympus, Center Valley, PA) at excitation and emission 
wavelengths of 515/590 nm and 450/515 nm, respectively, using a CCD camera (Retiga-
2000R; QImaging, Surrey, BC, Canada), operated, processed and analyzed with the 
Image-Pro® Plus 5.1 software (Media Cybernetics, Inc. Bethesda, MD). Under a 400 X 
magnification, the c-Fos immunofluorescence was quantified bilaterally in the 
hypothalamus and unilaterally in the brainstem with a representative rectangular 488 X 
720 pixel area using the software. However, this quantitative approach was inapplicable 
to the NPY assessment due to lack of a localized pattern for quantification using pixel 
values; these were thus assessed visually (e.g., Figures 3.9).  
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3.B.8 STATISTICAL ANALYSES 
Results of the food and water intake, body weight gain and c-Fos positive pixel 
counts were expressed as group mean±standard error (SE). Statistical analyses for group 
comparison were carried out using Prism® 4 (GraphPad Software, San Diego, CA) or 
JMP® 8 (SAS Institute, Inc., Cary, NC), employing p<0.05 as significant. In Figure 3.1, 
however, repeated-measures analysis of variance (ANOVA) or paired t-test was used. In 
Tables 3.1-3.3 and Figures 3.2-3.5 and 3.8, one-way ANOVA was employed to identify 
the statistical differences between groups. In Figure 3.6, two-way ANOVA was used to 
identify the significant difference. Post-hoc analysis for multiple comparison testing was 
performed by the Tukey’s or Dunnett’s method, the latter being used to compare multiple 
test groups to the control group, but not among each other, e.g., the data in Figure 3.2. 
3.C RESULTS 
 
3.C.1 PHYSIOLOGICAL MONITORING OF FOOD AND WATER INTAKE AND 
BODY WEIGHT GAIN 
Because the intra- and oro-tracheal instillation operations required the use of the 
short-acting isoflurane anesthesia, with and without surgical incision, respectively, their 
impact on the food and water intake and body weight gain was first evaluated. Figure 3.1 
shows the daily food and water intake (Panels A and C) and cumulative body weight gain 
(Panels B and D) during 7-day acclimatization and subsequent 2 days following single 
intratracheal instillation of saline (Panels A and B) or 8 days of daily repeated orotracheal 
instillation of saline (Panels C and D). Single intratracheal instillation of saline on day 7 
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(Panels A and B) was shown to cause significant reduction in the daily food intake and 
body weight gain by 11.1±2.7 and 85.6±24.2 %, respectively, on day 8, compared to the 
mean values during the acclimatization period (p<0.05); the daily water intake was also 
reduced, but insignificantly. However, these values appeared to be recovered on day 9, as 
all the values became statistically consistent with those during the acclimatization (Panels 
A and B). In contrast, despite a lack of surgical incision, the daily repeated orotracheal 
instillations of saline during 7 days of the dosing period were shown to significantly 
reduce the averaged daily food intake and body weight gain (i.e., the slope) by 7.9±1.7 
and 44.7±6.5 %, respectively, compared to the values during the acclimatization (p<0.05; 
Panels C and D); the daily water intake was only minimally reduced (Panel C). Hence, 
regardless of whether the intra- or oro-tracheal instillation was employed, the food intake 
and body weight gain were reduced, which suggested that these reductions were caused 
by the anesthesia rather than the surgical incision. From these observations, it was clear 
that the saline control values were necessary to assess the effects of PYY administered to 
the lungs. 
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Figure 3.1 Daily (
 
) food and (
 
) water intake (Panels A and C) and (
 
) cumulative 
body weight gain (Panels B and D) during 7-day acclimatization and 
subsequent periods of single intratracheal instillation (Panels A and B; n=12) 
or daily repeated orotracheal instillations for 7 days (Panel C and D; n=7) of 
saline in freely feeding rats. The mean values of food and water intake are 
shown with solid and dotted lines, respectively, in Panels A and C, while the 
lines in Panels C and D represent the result of linear regression. The 
instillation is shown with . The data represent mean±standard error (SE); * 
and ** indicate p<0.05, compared to the corresponding mean values during 
the 7-day acclimatization via the repeated measures ANOVA (Panel A and 
B) and paired t-test (Panel C and D).  
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3.C.2 FOOD INTAKE SUPPRESSION FOLLOWING SINGLE PULMONARY 
ADMINISTRATION OF PYY 
           Figure 3.2 shows the cumulative food intake at 2, 4, 6 and 24 h following single 
intratracheal instillation of saline and PYY3-36 at 0.08, 0.40 and 0.80 mg/kg. The highest 
dose of PYY3-36 at 0.80 mg/kg caused significant and maximum food intake suppression 
by 35.1±5.7 % at 4 h following instillation and lower, yet still significant suppression by 
19.7±4.2 % at 6 h, compared to the saline control (p<0.05). This food intake suppression 
was not observed at 2 and 24 h, demonstrating its time-related and short-lived effect. 
Meanwhile, the lower doses of PYY3-36 at 0.40 and 0.08 mg/kg failed to cause significant 
food intake suppression at any times, suggesting that the effect was also dose-related with 
this single pulmonary administration of PYY3-36. The water intake and body weight gain 
were statistically consistent across groups 24 h post-instillation, as shown in Table 3.1.  
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Figure 3.2
 
Cumulative food intake at 2, 4, 6 and 24 h following single intratracheal 
instillation of saline ( ; n=12) and PYY3-36 at 0.08 mg/kg ( ; n=8), 0.40 mg/kg 
( ; n=7) and 0.80 mg/kg ( ; n=7) in freely feeding rats. Data represent mean±SE, 
* indicates p<0.05, compared to the corresponding values in the saline control, derived 
from the one-way ANOVA, followed by the Dunnett’s test.  
 
 
Table 3.1 The 24 h water intake and body weight gain following single intratracheal 
instillation of saline (n=12) and PYY3-36 at 0.08 (n=8), 0.40 (n=7) and 
0.80 (n=7) mg/kg. Data represent mean±SE.  
Group Water intake (g) Body weight gain (g) 
Saline 29.6±1.3 1.0±1.7 
PYY 3-36 0.08 mg/kg 32.0±1.8 4.7±0.5 
PYY 3-36 0.40 mg/kg 29.6±1.2 3.0±0.4 
PYY 3-36 0.80 mg/kg 30.7±0.7 2.8±0.8 
There were no between-group differences via one-way ANOVA (p>0.05). 
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           Figure 3.3 shows the cumulative food intake at 2, 4, 6 and 24 h following single 
administration of saline and PYY3-36 at 0.80 mg/kg via intra- and oro-tracheal instillation; 
the data for the intratracheal instillation were adopted from Figure 3.2. The cumulative 
food intake following intra- and oro-tracheal instillation of saline almost completely 
mirrored at all time points. Moreover, irrespective of whether intra- and oro-tracheal 
instillation was employed, significant 31-35 % and 20-24 % suppression of the 4 and 6 h 
food intake, respectively, was equally observed with 0.80 mg/kg of PYY3-36, as % food 
intake suppression at each of the time points was insignificantly different between these 
dosing techniques (p>0.05). It was most likely therefore that the intra- and oro-tracheal 
instillations caused equivalent food intake suppression for PYY3-36 at 0.80 mg/kg. 
Figure 3.4 shows the cumulative food intake at 2, 4, 6 and 24 h following 
subcutaneous injection of PYY3-36 at 0.80 mg/kg in the sham-operated animals, compared 
to that following intratracheal instillation of saline and PYY3-36 at 0.80 mg/kg; the latter 
comparator data were adopted from Figure 3.2. Subcutaneous injection of PYY3-36 at 
0.80 mg/kg was shown to cause 35.0±8.5 and 30.6±5.0 % food intake suppression at 4 
and 6 h, respectively, which was equivalent to that following pulmonary administration 
(p>0.05). Hence, when compared at the identical dose at 0.80 mg/kg, lung delivery of 
PYY3-36 was equipotent to subcutaneous injection. Meanwhile, as shown in Table 3.2, 
subcutaneous injection of PYY3-36 affected neither the water intake nor the body weight 
gain at 24 h (p>0.05). 
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Figure 3.3 Cumulative food intake at 2, 4, 6 and 24 h following single intratracheal 
instillation of saline ( ; n=12) and PYY3-36 at 0.80 mg/kg ( ; n=7) 
and orotracheal instillation of saline ( ; n=7) and PYY3-36 at 0.80 mg/kg 
( ; n=7) in freely feeding rats. Data represent mean±SE, * and ** 
indicate p<0.05, compared to the corresponding values in each of the saline 
controls, respectively, derived from the one-way ANOVA, followed by the 
Tukey’s test.  
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Figure 3.4 Cumulative food intake at 2, 4, 6 and 24 h following single subcutaneous 
injection of PYY3-36 at 0.80 mg/kg in the sham-operated animals ( ; 
n=5), compared to those following intratracheal instillation of saline ( ; 
n=12) and PYY3-36 at 0.80 mg/kg ( ; n=7) in freely feeding rats. The 
data represent mean±SE, * indicates p<0.05, compared to the corresponding 
values in the saline control, derived from the one-way ANOVA, followed by 
the Tukey’s test.  
 
 
Table 3.2 The 24 h water intake and body weight gain following single intratracheal 
instillation (IT) of saline (n=12) and PYY3-36 at 0.80 mg/kg (n=7) in freely 
feeding rats and subcutaneous injection (SC) of PYY3-36 at 0.80 mg/kg in the 
sham-operated animals (n=5). Data represent mean±SE.  
Group Water intake (g) Body weight gain (g) 
IT Saline 29.6±1.3 1.0±1.7 
IT PYY 3-36 0.80 mg/kg 30.7±0.7 2.8±0.8 
SC PYY 3-36 0.80 mg/kg 32.0±1.2 3.6±1.2 
 There were no between-group differences via one-way ANOVA (p>0.05). 
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Figure 3.5 shows the cumulative food intake at 2, 4, 6 and 24 h following single 
intratracheal instillation of PYY1-36 at 0.90 mg/kg and PYY13-36 at 0.60 mg/kg, compared 
to that for the saline control and PYY3-36 at 0.80 mg/kg; the latter comparator data were 
adopted from Figure 3.2. These PYY1-36 and PYY13-36 doses were chosen to be 
0.20 µmol/kg, equimolar to the PYY3-36 dose causing significant food intake suppression 
(i.e., 0.80 mg/kg) in Figure 3.2, in order to compare their molar potencies with this 
pulmonary delivery. Intriguingly, PYY1-36, the endogenously secreted form of PYY, 
exhibited significant 32.2±5.3 and 28.0±6.4 % suppression of the cumulative food intake 
at 4 and 6 h, respectively, following pulmonary administration, compared to the saline 
control (p<0.05). In fact, these values were statistically equivalent to those of PYY3-36, 
i.e., 35.1±5.7 and 19.7±4.2 %, respectively (p>0.05), suggesting that PYY1-36 and 
PYY3-36 were equipotent with respect to their 4 and 6 h food intake suppressions 
following this pulmonary administration. Moreover, the cumulative food intake for 
PYY1-36 at 24 h remained significantly lower than that of the saline control by 13.9±3.9 
% (p<0.05), which may have implied the sustained effect of this endogenously secreted 
gut peptide following pulmonary administration. In contrast, the active fragment peptide, 
PYY13-36 at 0.20 µmol/kg (0.60 mg/kg) caused slight and insignificant suppression of the 
cumulative food intake by 18-21 % at 4 and 6 h, compared to the saline control (p>0.05), 
demonstrating that this smaller peptide was not as potent as PYY3-36. As shown in 
Table 3.3, neither PYY1-36 nor PYY13-36 affected the 24 h water intake and body weight 
gain. 
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Figure 3.5 Cumulative food intake at 2, 4, 6 and 24 h following single intratracheal 
instillation of saline ( ; n=12), PYY3-36 at 0.80 mg/kg ( ; n=7), 
PYY1-36 at 0.90 mg/kg ( ; n=6) and PYY13-36 at 0.60 mg/kg ( ; n=7) 
in freely feeding rats. Data represent mean±SE, * indicates p<0.05, 
compared to the corresponding values in the saline control, derived from the 
one-way ANOVA, followed by the Tukey’s test.  
 
 
Table 3.3 The 24 h water intake and body weight gain following single intratracheal      
instillation of saline (n=12), PYY3-36 at 0.80 mg/kg (n=7), PYY1-36 at 
0.90 mg/kg (n=6) and PYY13-36 at 0.60 mg/kg (n=7). Data represents 
mean±SE.  
Group Water intake (g) Body weight gain (g) 
Saline 29.6±1.3 1.0±1.7 
PYY3-36 0.80 mg/kg 30.7±0.7 2.8±0.8 
PYY1-36 0.90 mg/kg 29.6±2.2 0.0±1.3 
PYY13-36 0.60 mg/kg 28.2±1.6 0.9±1.1 
There were no between-group differences via one-way ANOVA (p>0.05). 
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3.C.3 FOOD INTAKE SUPPRESSION AND REDUCED BODY WEIGHT GAIN 
DURING AND FOLLOWING DAILY REPEATED PULMONARY 
ADMINISTRATION OF PYY3-36  
Figure 3.6 shows the profiles of cumulative food intake and body weight gain 
during and following daily repeated orotracheal instillations of saline and PYY3-36 at 0.08 
and 0.80 mg/kg for 7 days. The cumulative food intake for PYY3-36 at 0.80 mg/kg was 
significantly lower than that for the saline control on day 5 and thereafter (p<0.05), which 
resulted in 16.7±8.6 % suppression by day 8. In this context, % food intake suppression 
4 h post-instillation on day 1, 4 and 7 remained consistent, exhibiting 30.8±6.3, 32.4±9.8 
and 35.7±11.0 %, respectively (p>0.05). Therefore, this continued and consistent food 
intake suppression after each daily instillation likely enabled significant reduction of the 
cumulative food intake by day 5, despite its short-lived (4-6 h) effect on a daily basis, as 
seen in Figure 3.2. Correspondingly, significant reduction of the cumulative body weight 
gain was achieved with PYY3-36 at 0.80 mg/kg on day 5 and thereafter (p<0.05), yielding 
39.4±11.0 % reduction by day 8. Clearly, this reduced body weight gain was attributed to 
the repeated daily instillations, as single instillation did not cause such a reduction. In 
contrast, the lower 0.08 mg/kg dose of PYY3-36 caused no appreciable reductions of the 
food intake and body weight gain, as their profiles effectively overlaid with those for the 
saline control (Figure 3.6). The daily water intake remained unaffected by this repeated 
administration of PYY3-36 for 7 days (data not shown).      
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Figure 3.6 Cumulative A) food intake and B) body weight gain during and following 
daily repeated orotracheal instillations of saline ( ; n=7) and PYY3-36 at 
0.08 ( ; n=6) and 0.80 mg/kg ( ; n=7) for 7 days in freely feeding rats. 
Data represent mean±SE; * indicates p<0.05, compared to the corresponding 
values for the saline control, derived from the two-way ANOVA, followed 
by the Tukey’s test. 
 
  
A) 
B) 
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3.C.4 c-FOS AND NPY EXPRESSION IN THE HYPOTHALAMUS AND 
BRAINSTEM FOLLOWING PULMONARY ADMINISTRATION OF PYY 
The immunofluorescence staining protocols had been validated, evidenced by the 
absence of non-specific antibody binding and auto-fluorescence on the brain sections 
(Appendix 2). Thus, Figure 3.7 shows the micrographs of c-Fos specific expression in the 
ARC region of the right and left hypothalamus in each rat (Panels A and B, respectively), 
taken at 4 h following single intratracheal instillation of saline, PYY3-36 at 0.08 and 
0.80 mg/kg, PYY1-36 at 0.90 mg/kg and PYY13-36 at 0.60 mg/kg. Each group employed 
three animals to ensure accurate and reliable c-Fos expression. In fact, as shown in 
Figure 3.8, the c-Fos positive pixel counts in each group were fairly reproducible. 
Overall, the results of c-Fos expression in response to each of the PYYs were consistent 
with those of food intake shown in Figures 3.2 and 3.5. At 4 h, the c-Fos expression in 
the ARC region appeared to be the highest for PYY3-36 at 0.80 mg/kg and PYY1-36 at 
0.90 mg/kg, compared to the lower 0.08 mg/kg dose of PYY3-36 or PYY13-36 at 
0.60 mg/kg. Indeed, their c-Fos positive pixel counts in the ARC region were 5.0- and 
4.6-fold higher than those in the saline control, respectively, as shown in Figure 3.8. In 
contrast, such c-Fos positive pixel counts were shown to be moderately increased by 2.8- 
and 2.6-fold, respectively, in response to 0.08 mg/kg PYY3-36 and 0.60 mg/kg PYY13-36. It 
was quite likely therefore that the food intake suppression by PYYs administered to the 
lung was quantitatively associated with this neuronal activation represented by the 
increased c-Fos expression in the hypothalamus ARC region. Likewise, the NPY protein 
expression in the ARC region shown in Figure 3.9 appeared to be the lowest for 
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0.80 mg/kg PYY3-36 and 0.90 mg/kg PYY1-36, compared to that for 0.08 mg/kg PYY3-36, 
0.60 mg/kg PYY13-36 or saline. This was again in line with the results of food intake 
suppression by these peptides shown in Figures 3.2 and 3.5, thereby lending a strong 
support that the mechanism of food intake suppression following pulmonary 
administration of PYY involved this reduced expression of orexigenic NPY in the 
hypothalamus ARC region, as suggested in its physiological appetite control (Karra et al, 
2009; le Roux et al., 2005).  
          This increased c-Fos expression within the brain in response to 0.80 mg/kg PYY3-36 
was further confirmed at 4 h following the 8th orotracheal instillation in the repeated daily 
administration protocol. Figures 3.10-3.12 show the micrographs of c-Fos specific 
expression in the hypothalamus ARC and PVN as well as the brainstem AP regions, 
respectively, following the 8th saline or 0.80 mg/kg PYY3-36 instillation. Like the single 
instillation study (Figure 3.7), the c-Fos expression was substantially increased in the 
ARC region following PYY3-36 instillation. However, it was only marginally increased in 
the PVN region and remained negligible in the brainstem AP region. Hence, it was likely 
that the food intake suppression by PYY3-36 administered to the lung was predominantly 
mediated via its direct interaction with the hypothalamus ARC regions, presumably via 
the Y2-receptors; however its subsequent signal projection to the PVN region remained 
substantially low. In contrast, the brainstem AP region appeared to be negligibly involved 
in the food intake suppression for PYY3-36 administered to the lung.  
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Figure 3.7 Immunofluorescence micrographs of the 30 µm thick coronal brain sections showing c-Fos 
specific expression in the right hypothalamus ARC region in each rat (n=3), taken at 4 h 
following single instillation of saline, PYY3-36 at 0.08 and 0.80 mg/kg, PYY1-36 at 0.90 mg/kg 
and PYY13-36 at 0.60 mg/kg. The micrograph images were taken under 400X magnification, 
and the scale bars represent 50 µm. The rectangular boxes represent the areas of the ARC 
region chosen for the c-Fos count in Figure 3.8. 
       Saline                                    PYY3-36                                                PYY1-36                              PYY13-36                                                                                  
                                                       
0.08 mg/kg            0.80 mg/kg           0.90 mg/kg              0.60 mg/kg           
A) Right ARC 
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Figure 3.7 Immunofluorescence micrographs of the 30 µm thick coronal brain sections showing c-Fos specific 
expression in the left hypothalamus ARC region in each rat (n=3), taken at 4 h following single 
instillation of saline, PYY3-36 at 0.08 and 0.80 mg/kg, PYY1-36 at 0.90 mg/kg and PYY13-36 at 
0.60 mg/kg. The micrograph images were taken under 400X magnification, and the scale bars 
represent 50 µm. The rectangular boxes represent the areas of the ARC region chosen for the c-Fos 
count in Figure 3.8. 
       Saline                                    PYY3-36                                                       PYY1-36                              PYY13-36                                                                                  
                                                       
0.08 mg/kg            0.80 mg/kg               0.90 mg/kg              0.60 mg/kg            
B) Left ARC 
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Figure 3.8 c-Fos positive pixel counts in the bilateral rectangular 488 X 720 pixel areas 
of the hypothalamus ARC regions in different groups of animals, taken at 4 h 
following single intratracheal instillation of saline, PYY3-36 at 0.08 and 
0.80 mg/kg, PYY1-36 at 0.90 mg/kg and PYY13-36 at 0.60 mg/kg. Data 
represent mean±SE (n=3). * indicates p<0.05, compared to the saline control 
value, derived from one-way ANOVA followed by the Tukey’s test. 
 
          Saline            PYY3-36          PYY1-36        PYY13-36 
                                              
0.80 mg/kg     0.90 mg/kg     0.60 mg/kg 
                 0.08                   0.80 
                      PYY3-36 (mg/kg) 
    Saline 
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          Saline                                   PYY3-36                                                                 PYY1-36                                   PYY13-36                                                                                  
                                                         
0.08 mg/kg            0.80 mg/kg                      0.90 mg/kg                  0.60 mg/kg            
Figure 3.9 Immunofluorescence micrographs of the 30 µm thick coronal brain sections showing NPY specific 
expression in the right hypothalamus ARC region in each rat (n=3), taken at 4 h following single 
instillation of saline, PYY3-36 at 0.08 and 0.80 mg/kg, PYY1-36 at 0.90 mg/kg and PYY13-36 at 
0.60 mg/kg. The micrograph images were taken under 100X magnification, and the scale bars 
represent 50 µm. The arrows indicate the hypothalamus ARC region. 
 
A) Right ARC 
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          Saline                                   PYY3-36                                                                 PYY1-36                                   PYY13-36                                                                                  
                                                         
0.08 mg/kg            0.80 mg/kg                      0.90 mg/kg                  0.60 mg/kg            
Figure 3.9 Immunofluorescence micrographs of the 30 µm thick coronal brain sections showing NPY 
specific expression in the left hypothalamus ARC region in each rat (n=3), taken at 4 h following 
single instillation of saline, PYY3-36 at 0.08 and 0.80 mg/kg, PYY1-36 at 0.90 mg/kg and PYY13-36 
at 0.60 mg/kg. The micrograph images were taken under 100X magnification, and the scale bars 
represent 50 µm. The arrows indicate the hypothalamus ARC region. 
B) Left ARC 
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PYY3-36  
0.80 mg/kg     Saline  
PYY3-36  
0.80 mg/kg     Saline  
Right ARC Left ARC 
Figure 3.10 Immunofluorescence micrographs of the 30 µm thick coronal brain sections showing  
c-Fos specific expression in the right and left hypothalamus ARC regions in each rat 
(n=2), taken at 4 h following the 8th orotracheal instillation of saline and PYY3-36 at 
0.80 mg/kg on day 8 of the repeated daily administration protocol. The micrograph 
images were taken under 400X magnification, and the scale bars represent 50 µm. 
The arrows indicate the hypothalamus ARC region. 
54
 
  55 
 
 
 
 
  
PYY3-36  
0.80 mg/kg     Saline  
PYY3-36  
0.80 mg/kg     Saline  
Right PVN Left PVN 
Figure 3.11 Immunofluorescence micrographs of the 30 µm thick coronal brain sections showing 
c-Fos specific expression in the right and left hypothalamus PVN regions in each rat 
(n=2), taken at 4 h following the 8th orotracheal instillation of saline and PYY3-36 at 
0.80 mg/kg on day 8 of the repeated daily administration protocol. The micrograph 
images were taken under 400X magnification, and the scale bars represent 50 µm. 
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PYY3-36  
0.80 mg/kg     Saline  
Figure 3.12 Immunofluorescence micrographs of the 30 µm thick coronal brain sections 
showing  c-Fos specific expression in the unilateral brainstem AP region in each 
rat (n=2), taken at 4 h following the orotracheal instillation of saline and PYY3-36 
at 0.80 mg/kg on day 8 of the repeated daily administration protocol. The 
micrograph images were taken under 400X magnification, and the scale bars 
represent 50 µm. 
AP 
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3.D DISCUSSION  
 
This study is the first demonstration that pulmonary delivery of PYY could 
suppress food intake and reduce body weight gain significantly in freely feeding rats, 
thereby leading to the proof-of-concept for its needle- and pain-free administration to 
control the appetite. The food intake suppression appeared to be time- and dose-related 
for PYY3-36, exhibiting 4-6 h suppression at 0.80 mg/kg (Figure 3.2). Even so, its               
daily repeated administration for 7 days enabled 39.4±11.0 % reduction of the cumulative 
body weight gain, as a result of the continued and consistent 4 h food intake suppression 
by 30-36 % (Figure 3.6). These effects appeared to be related to the substantially reduced 
orexigenic NPY expression in the hypothalamus ARC region, accompanied with the 
neuronal activation represented by the 5.0-fold increased c-Fos expression (Figures 3.7-
3.11). In contrast, the involvement of the indirect vagal pathway appeared unlikely, as 
c-Fos expression was negligible in the brainstem AP region (Figure 3.12). Notably, the 
endogenously secreted form of PYY, PYY1-36 caused equipotent and possibly, sustained 
food intake suppression, compared to PYY3-36 in this study of pulmonary delivery, while 
its fragment peptide, PYY13-36 was rather less potent, despite its expected higher lung 
absorption (Figure 3.5).  
It was quite essential in this study to first ensure that physiological food and water 
intake and body weight gain were minimally affected by the use of anesthesia and 
surgical incision during PYY administration to the lung. As demonstrated previously 
(Abbott et al., 2006), the acclimatization and habituation of animals were critical, which 
required individual housing in the metabolic cages for the 7-day period in the tightly 
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controlled animal care facility. The isoflurane exposure was minimized, such that rats 
regained consciousness typically within 4 min post-administration. Even so, the daily 
food intake and body weight gain post-saline administration were slightly lower than 
those during the acclimatization (Figure 3.1). This limitation appeared to arise from the 
anesthesia rather than the surgical incision, as the food intake profiles almost perfectly 
mirrored between the intra- and oro-tracheal instillation of saline, the techniques only 
differing in the presence and absence of the surgical incision, respectively (Figure 3.1). 
Fortunately, both dosing methods still appeared to be sufficiently sensitive and relevant 
to study the anorectic effects of PYY, as subcutaneous injection of PYY3-36 at 0.80 mg/kg 
in the sham-operated rats was shown to cause % food intake suppression, consistent with 
the literature (Tschöp et al., 2004). Indeed, this consistency with the literature supported 
our notion that the food intake suppression in this study was not caused simply by the 
adverse effects, such as behavioral impairment. 
Independent of whether intra- or oro-tracheal instillation was employed, significant 
and equivalent % food intake suppression was observed at 4 and 6 h for PYY3-36 at 
0.80 mg/kg (Figure 3.3). While this implied that these two lung dosing techniques 
enabled similar lung-regional distribution, yielding comparable lung absorption kinetics 
of PYY3-36, the 0.80 mg/kg dose was considerably higher than the effective doses for 
intravenous or intraperitoneal injection reported with rodents in the literature (e.g., 0.01-
0.10 mg/kg; Tschöp et al., 2004). This simply represented a moderate-to-low absolute 
bioavailability for this 4 kDa peptide following pulmonary administration in rats, as has 
been the case for most macromolecules with this molecular weight range (<30 %; Byron 
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and Patton., 1994). Even so, this short-term (4-6 h) food intake suppression appeared to 
continue consistently during the daily repeated instillation for 7 days, which led to 
successful 39.4±11.0 % reduction of the cumulative body weight gain by day 8 
(Figure 3.6). In this context, recent studies demonstrated that PYY3-36 also increased 
energy expenditure and altered fuel partitioning in favor of fat oxidation and reduced 
adiposity (Guo et al., 2006; van den Hoek et al., 2007), in addition to food intake 
suppression. Furthermore, the literature also suggested a compensatory increase of the 
food intake post-administration or development of tolerance during continued or repeated 
administration for PYY3-36, resulting in only transient reduction in the food intake and 
body weight gain (Challis et al., 2004; Moran et al., 2005; Tschöp et al., 2004). While 
such aspects remain uncertain for pulmonary delivery, recent studies with subcutaneous 
infusion (Pittner et al., 2004, Roth et al., 2007 and Unmiappan et al., 2006) and daily 
intermittent intravenous infusion (Chelikani et al., 2006) have rather shown successful 
reduction of body weight gain in rodents, like the present study (Figure 3.6). Hence, this 
may have implications with the PYY3-36 dosing design, e.g., dose, frequency and period, 
in rodents, in order to maintain the food intake suppression and reduce the body weight 
gain in the long-term. Meanwhile, when administered via injections at high doses, 
PYY 3-36 was shown to be associated with adverse events including conditioned taste 
aversion (Halatchev and Cone, 2005). Such adverse behavioral events were not assessed 
in this study of pulmonary administration of PYY3-36 and thus, need to be clarified. 
In rodents, the food intake suppression of the endogenously secreted form of PYY, 
PYY1-36, was shown to be equipotent to that of PYY3-36 following subcutaneous infusion, 
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attributed to its efficient conversion to the “active” PYY3-36 by DPPIV (Unmiappan et al., 
2006). However, intravenous infusion of PYY1-36 resulted in an order of magnitude less 
potent food intake suppression than that of PYY3-36 (Chelikani et al., 2005). In humans, 
PYY1-36 had no inhibitory effects on the appetite rating with subcutaneous injection, 
although increased satiety was observed following PYY3-36 administration (Sloth et al., 
2007). Hence, the literature has been mixed and inconclusive, as to the appetite 
suppressive potency of PYY1-36, when administered exogenously. In this regard, it was 
intriguing that the food intake suppression by PYY1-36 and PYY3-36 was shown to be 
equipotent following pulmonary administration in the present study (Figure 3.5). This 
was presumably by virtue of sufficient conversion of PYY1-36 to PYY3-36 by DPPIV, not 
only in the blood but also in the lung. DPPIV has been shown to be more abundant in the 
rat lung than the serum or intestinal mucosa, known to cause substantial degradation of 
its substrates (Kera et al., 1999; van der Velden and Hulsmann, 1999). Moreover, there is 
no compelling evidence that enzymatic conversion of PYY1-36 in the blood circulation is 
instantaneous. In fact, PYY3-36 was shown to account for only 36 and 64 % of the total 
PYY immunoreactivity in the basal and postprandial plasma, respectively (Grandt et al., 
1994). Supportively, the 3 h in vitro incubation of PYY1-36 and DPPIV still detected > 50 
% of remaining PYY1-36 (Unmiappan et al., 2006). Thus, if this were the case, PYY1-36 
administered to the lung could cause sustained food intake suppression than PYY3-36, as 
observed in Figure 3.5, by virtue of its gradual conversion to the “active” PYY3-36 by 
DPPIV in the lung and systemic circulation. Meanwhile, despite higher lung absorption 
expected due to its lower molecular weight (3.0 kDa), the fragment peptide, PYY13-36 was 
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marginally effective following pulmonary administration (Figure 3.5). This 3.0 kDa 
peptide retained the Y2-receptor related activities, such as NPY binding displacement in 
the rat brain (Walker and Miller, 1988) and inhibition of catecholamine synthesis in the 
rat mesenteric bed (Westfall et al., 2006). However, such in vitro molar potencies for 
PYY13-36 were less than a half of those for the full length peptide (Wahlestedt et al., 1986; 
Walker and Miller., 1988; Westfall et al., 2006). Hence, it can be implied that higher lung 
absorption of PYY13-36 expected from its lower molecular weight could not overcome the 
reduced molar intrinsic potency to the Y2-receptor, when administered at the equimolar 
dose of PYY1-36 or PYY3-36.  
Food intake suppression of PYY3-36 has been primarily attributed to reduction of 
orexigenic NPY expression in the brain hypothalamus ARC region via its interaction with 
the Y2-receptor (Ballantyne, 2006; Karra et al., 2009; le Roux and Bloom, 2005). 
Nevertheless, peripheral injection of PYY3-36 was also shown to cause neuronal activation 
of c-Fos in the brainstem and increase vagal afferent firing, implying the role of the vagal 
nerve on the PYY’s appetite suppression; this may have also been related to its local 
actions on delayed GI emptying (Abbott et al., 2005; Dumont et al., 2007; Karra et al., 
2009; Koda et al., 2005; le Roux and Bloom, 2005). Hence, in this study, c-Fos 
expression was assessed both in the hypothalamus (ARC and PVN) and brainstem (AP) 
to clarify the target brain locations for PYYs administered to the lung. As consistently 
shown in Figures 3.7-3.12, the hypothalamus ARC appeared to be the primary location, 
evidenced by the c-Fos activation and NPY reduction. This was quite reasonable, based 
on the evidence that the lung allows absorption of 3-4 kDa macromolecular peptides like 
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PYY into the systemic circulation (Byron and Patton, 1994), and such molecules could 
readily access the hypothalamus ARC located in close proximity to the deficient blood-
brain-barrier (Broadwell and Brightman, 1976). In contrast, for PYY3-36 administered to 
the lung, the involvement of the brainstem AP via vagal stimulation in its food intake 
suppression was unlikely, as c-Fos activation was negligible even following repeated 
daily instillations (Figures 3.10-3.12). Meanwhile, although afferent inputs can arrive 
from both the ARC and brainstem, the “second-order” neurons in the PVN were not 
activated following pulmonary administration of PYY3-36 (Figure 3.11). This was of 
interest for further clarification, as direct interaction of PYY with this PVN was shown to 
cause rather appetite stimulation (Stanley et al., 1985). Note that this mechanistic 
deduction is not necessarily physiological, but rather specific to PYY administered to the 
lung. 
The feasibility of developing PYY formulations for inhalation in humans would 
largely depend on its dose to be delivered to the lungs, as only a limited mass can be 
inhaled due to the inspiratory capacity (Patton and Byron, 2007). In humans, the effective 
dose of PYY3-36 for intravenous injection was 0.0002 mg/kg (Batterham et al., 2002). 
Thus, assuming the moderate-to-low absolute bioavailability of 10-30 % for pulmonary 
delivery of PYY3-36 in humans, 0.0007-0.002 mg/kg would be required for the effective 
appetite suppression. This would correspond to 0.05-0.14 mg for a 70 kg human, which 
was considerably lower than 3 mg of insulin formulated in Exubera® (Rave et al., 2005). 
Therefore, this argues the feasibility of PYY formulation for inhalation in humans based 
on the projected dose necessary to exhibit appetite suppression. 
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3.E CONCLUSIONS 
 
Food intake suppression and reduced body weight gain following pulmonary 
administration of PYYs was successfully shown in rats using the validated housing and 
monitoring system and minimally invasive lung dosing techniques under the short acting 
isoflurane anesthesia. Single pulmonary administration of PYY3-36 exhibited dose-related 
food intake suppression where the highest dose at 0.80 mg/kg caused significant food 
intake suppression 4 and 6 h post-instillation. The endogenously secreted form of PYY, 
PYY1-36 was shown to be equipotent to PYY3-36 with respect to the 4-6 h food intake 
suppression following pulmonary administration, while possibly exhibiting the sustained 
effect by 24 h. In contrast, the active fragment peptide, PYY13-36, was less potent, thereby 
deriving the rank-order of the potency, PYY3-36 ~ PYY1-36 > PYY13-36. When 
administered daily for 7 days, PYY3-36 was shown to reduce body weight gain by virtue 
of continued 4-6 h food intake suppression on a daily basis. These effects appeared to 
arise from the hypothalamus ARC, as its orexigenic NPY expression was reduced and the 
c-Fos protein was activated. However, such c-Fos activation was not observed in the 
brainstem, suggesting that the PYY’s food intake suppression and reduced body weight 
gain was likely controlled by the central nervous system, rather than the vagal 
stimulation. Overall, this chapter served the first proof-of-concept for successful food 
intake suppression for PYY by pulmonary delivery in rats, while further investigations 
are clearly necessary to address its clinical feasibility for appetite control in the obesity 
management. 
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CHAPTER 4 
 
PULMONARY DELIVERY OF OXYNTOMODULIN (OXM) 
FOR FOOD INTAKE SUPPRESSION AND REDUCED 
BODY WEIGHT GAIN IN RATS 
 
 
4.A INTRODUCTION 
Oxyntomodulin (OXM1-37) is an anorectic gut secreted peptide hormone,                     
co-secreted postprandially with PYY from the intestinal L-cells, in response to calorie 
intake (Chaudhri et al., 2008). While this has logically speculated a need and/or different 
roles of these two peptides in physiological appetite control, recent studies have 
demonstrated that OXM1-37 alone could suppress food intake and reduce body weight 
gain following parenteral injections, similar to PYY (Dakin et al., 2001; Dakin et al., 
2004). These effects appear to result from its direct brain interaction with the GLP-1 
receptors possibly together with local GI effects mediated by vagal stimulation (Cohen et 
al., 2003; Dakin et al., 2002; Dakin et al., 2004; Druce et al., 2009), although the 
subsequent signal transduction cascade for food intake suppression remains largely 
unknown. Moreover, promotion of energy expenditure and reduction of adiposity have 
been reported for this peptide, which have further confounded detailed clarification of its 
true mechanism (Dakin et al., 2002; Wynne et al., 2006).  
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Accordingly, like Chapter 3, this chapter aimed to demonstrate the potential of 
pulmonary delivery of OXM for food intake suppression and reduced body weight gain 
in rats. The endogenously secreted full length peptide, OXM1-37 was primarily tested 
following single and repeated pulmonary administration, while its “active” fragment 
peptides, OXM30-37 and NAc-OXM30-37 were also assessed with respect to their potencies. 
Immunofluorescence microscopy for neuronal activation of c-Fos was also carried out in 
different areas of the brain to identify the target locations involved in its appetite control. 
Hence, this chapter is focused on 1) the assessment of food intake suppression and 
reduced body weight gain for OXM1-37 following single and daily pulmonary 
administration, 2) the molar potency comparison of food intake suppression for the 
“active” fragment peptides, OXM30-37 and NAc-OXM30-37, and 3) the clarification of the 
target brain locations for OXM
 
administered to the lung through neuronal activation of 
c-Fos.   
 
4.B MATERIALS AND METHODS 
4.B.1    MATERIALS 
 
Lyophilized oxyntomodulin (OXM1-37; molecular weight of 4425 Da) and its         
C-terminal 8-amino acid fragment peptide (OXM30-37; molecular weight of 957.1 Da) 
were purchased from American Peptide Company, Inc. (Sunnyvale, CA) and Bachem 
Americas, Inc. (Torrance, CA), respectively. N-acetylated OXM30-37 (NAc-OXM30-37; 
molecular weight of 999.3 Da) was custom-synthesized by Bachem. Each of these 
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peptides was certified to contain 82.3, 84.0 and 73.0 % of the peptide by weight, with 
97.2, > 90 and > 90 % purity, respectively. These values were used to prepare OXM 
dosing solutions accurately from powder weights. Other reagents used in the animal 
experiments (e.g., isoflurane and sodium pentobarbital) and immunofluorescence 
microscopy (e.g., paraformaldehyde, Tissue Tek® OCT embedding medium, rabbit anti-
rat c-Fos and Cy3-labeled goat anti-rabbit IgG antibodies, normal goat serum, PBS, 
Triton-X 100 and bovine serum albumin) were obtained from the suppliers, as described 
in Chapter 3. 
 
4.B.2 ANIMALS 
Sprague-Dawley rats (male; specific-pathogen-free) weighing 250-275 g from 
Hilltop Lab Animals, Inc. (Scottdale, PA) were used under the adherence to the NIH 
Principles of the Laboratory Animal Care (NIH Publication # 85-23, revised in 1985) and 
the IACUC protocol (Protocol # AM10331) approved at VCU. As described in Chapter 
3, each animal was housed individually in a metabolic cage and acclimatized for 7 days 
in the animal care facility under the controlled conditions at 20-23 oC, 40-70 % relative 
humidity and 12-12 h light-dark cycling. Animals had free access to pre-weighed 
standard rat diet (Product # 7012; Harlan Teklad Global Diet, Boston, MA) and tap water 
throughout. During the acclimatization, the animals demonstrated physiological values of 
30.6±0.4 g, 30.7±0.3 g and 7.1±0.3 g (n=38) of the daily food and water intake and body 
weight gain, respectively.  
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4.B.3 FOOD INTAKE AND BODY WEIGHT GAIN FOLLOWING SINGLE AND 
REPEATED PULMONARY ADMINISTRATION  
Pulmonary administration of OXMs was carried out ~1 h prior to the beginning of 
the dark-phase (~5 PM) by orotracheal instillation only, as described in Chapter 3. 
Briefly, animals were first anesthetized in a chamber box by 4 % (v/v) isoflurane vapor 
(Ohmeda Tech 4 Surgivet®) and then placed in a supine position on the surgical board 
inclined at 60o under the heat lamp. Using the small animal fiber-optic laryngoscope (LS-
1; PennCentury, Inc.), the 8.5 cm PEEK extension tubing (O.D. 0.01 mm; Upchurch 
Scientific) attached to a 1 ml insulin syringe was inserted 3 cm down within the tracheal 
lumen, and 100 µl of various OXM solutions or saline was then directly instilled into the 
lung; the tip of the tubing was projected just before the tracheal bifurcation. The tubing 
was immediately removed, and the animals were left for recovery from the anesthesia; 
they typically gained consciousness within 5 min post-instillation. When repeated 
administration was tested, this operation was carried out daily for 7 days. 
Food and water intake and body weight gain were determined at different times 
by weight difference, as described in Chapter 3. For single pulmonary administration, rats 
were divided into the following 6 groups: 1) saline (n=8), 2-4) OXM1-37 at 0.05 (n=5), 
0.20 (n=6) or 0.50 mg/kg (n=6), 5) OXM30-37 at 0.10 mg/kg (n=6) and 6) NAc-OXM30-37 
at 0.10 mg/kg (n=6). Following administration, the dark-phase cumulative food intake at 
2, 4 and 6 h was determined, followed by monitoring of the 24 h intake. The daily water 
intake and body weight gain were also determined at 24 h. In the study of daily repeated 
pulmonary administration for 7 days, rats were divided into 2 groups; 1) saline (n=7) and 
 68 
2) OXM1-37 at 0.50 mg/kg (n=6); note that the saline control was identical to that used in 
Chapter 3. Daily food and water intake and body weight gain were monitored for 8 days 
post-first administration, while the dark-phase food intake was additionally determined 
2, 4 and 6 h post-instillation on day 1, 4 and 7. Some animals received the 8th orotracheal 
instillation on day 8 for the immunofluorescence assessment of c-Fos expression in the 
brain, as described below.  
 
4.B.4 IMMUNOFLUORESCENCE DETECTION OF c-FOS IN THE               
HYPOTHALAMUS AND BRAINSTEM 
The entire operating procedure was identical to that described in Chapter 3. At 4 h 
following single or the 8th orotracheal instillation in the repeated dosing protocol, rats 
were anesthetized with intraperitoneal injection of 50 mg/kg sodium pentobarbital. The 
brain was transcardially fixed with 4 % (w/v) paraformaldehyde for 20 min, and the 
midbrain and the brainstem were dissected. These tissue blocks were cryoprotected with 
30 % (w/v) sucrose in 0.2 M PBS for 48 h, embedded in the Tissue Tek® OCT medium, 
snap frozen and stored at -70 oC. Subsequently, 30 µm thick frozen coronal brain sections 
were cut using the cryostat (MICROM HM 550, Thermo Fisher Scientific), air-dried and 
stored at -20 oC until immunofluorescent c-Fos detection. For immunostaining, sections 
were selected to include the hypothalamus ARC and PVN and the brainstem area AP 
regions, referenced to the rat brain atlas (Kruger et al., 1995). The sections were then 
processed for removal of the embedding medium, followed by dehydration with 70-100 
% (v/v) serially graded ethanol solutions and rehydration with 0.2 M PBS containing 
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0.5 % (v/v) Triton-X 100 (PBST). The non-specific binding was blocked by 1 h 
incubation with PBST containing 4 % (w/v) bovine serum albumin, 5 % (w/v) dry non-
fat milk and 10 % (v/v) normal goat serum, for 1 h at room temperature. These sections 
were further incubated with the rabbit anti-rat c-Fos antibody (1:100 dilution) overnight 
at 4 oC and then, with Cy3-labeled goat anti-rabbit IgG antibody (1:200 dilution) for 1 h 
at room temperature. The Sudan black B stain was applied for 10 min, and the sections 
were finally cover-slipped. The c-Fos immunofluorescence images were captured under 
the fluorescence microscope (BX 40; Olympus) at excitation and emission wavelengths 
of 510 and 590 nm, respectively, using a CCD camera (Retiga-2000R; QImaging, Surrey) 
operated with the Image-Pro® Plus 5.1 software (Media Cybernetics Inc.). The c-Fos 
positive pixels were counted by the software, bilaterally in the hypothalamus ARC and 
PVN regions and unilaterally in the brainstem AP region, under 400X magnification 
using the representative rectangular area (488 X 720 pixels). 
 
4.B.5 STATISTICAL ANALYSIS 
 Results of the food and water intake, body weight gain and c-Fos positive pixel 
counts were expressed as group mean±standard error (SE). Statistical analyses were 
carried out with Prism® 4.0 (GraphPad Software) or JMP® 8 (SAS Institute, Inc.). In the 
single pulmonary OXM administration study, one-way ANOVA was employed to 
identify the statistical difference between groups (Table 4.1; Figures 4.1 and 4.3), 
followed by the post-hoc multiple comparisons by the Dunnett’s (Figure 4.1) or Tukey’s 
(Figure 4.3) test. In Table 4.2 and Figure 4.2, two-way ANOVA was used, followed by 
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the post-hoc multiple comparison testing with an unpaired t-test. In Figure 4.5, the c-Fos 
positive pixels were compared between groups with the unpaired t-test. In all statistical 
analyses, p<0.05 was considered to be significant. 
 
4.C RESULTS 
4.C.1 FOOD INTAKE SUPPRESSION FOLLOWING PULMONARY            
ADMINISTRATION OF OXM 
Figure 4.1 shows the cumulative food intake at 2, 4, 6 and 24 h following single 
orotracheal instillation of OXM1-37 at 0.05, 0.20 and 0.50 mg/kg, compared to the saline 
control. The highest dose of OXM1-37 at 0.50 mg/kg caused significant food intake 
suppression by 30.0±5.4 % at 4 h and 24.2±5.1 % at 6 h, compared to the saline control 
(p<0.05). This food intake suppression was not observed at 2 and 24 h, and the food 
intake between 6 and 24 h also remained consistent with that in the saline control. The 
food intake suppression was apparently dose-related, as the intermediate dose at 
0.20 mg/kg caused lower and insignificant food intake suppression by 17.6±8.2 % and 
17.7±6.2 % at 4 and 6 h, respectively, and the lowest dose at 0.05 mg/kg had no 
appreciable effects at any time points. Therefore, like PYY3-36 shown in Chapter 3, the 
food intake suppression of OXM1-37 was dose-related and short-lived (4-6 h) with this 
single pulmonary administration. The water intake and body weight gain 24 h post-
instillation were statistically consistent between groups (p>0.05), as shown in Table 4.1. 
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Figure 4.1 Cumulative food intake at 2, 4, 6 and 24 h following single orotracheal 
instillation of saline ( ; n=8) and OXM1-37 at 0.05 mg/kg ( ; n=5),  
0.20 mg/kg ( ; n=6) and 0.50 mg/kg ( ; n=6) in freely feeding rats. 
Data represent mean±SE, * indicates p<0.05, compared to the corresponding 
values for the saline control, derived from the one-way ANOVA, followed 
by the Dunnett’s test.  
 
 
Table 4.1 The 24 h water intake and body weight gain following single orotracheal 
instillation of saline (n=8) and OXM1-37 at 0.05 mg/kg (n=5), 0.20 mg/kg 
(n=6) and 0.50 mg/kg (n=6). Data represent mean±SE.  
 
Group Water intake (g) Body weight gain (g) 
Saline 32.9±0.8 4.3±0.9 
OXM1-37 0.05 mg/kg 41.7±7.0 0.4±1.1 
OXM1-37 0.20 mg/kg 33.0±1.8 3.9±1.0 
OXM1-37 0.50 mg/kg 29.0±1.1 2.9±0.9 
There were no between-group differences via one-way ANOVA (p>0.05). 
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The cumulative food intake and body weight gain profiles during daily pulmonary 
administration of saline and OXM1-37 at 0.50 mg/kg for 7 days are shown in Figure 4.2. It 
was until day 7 that the cumulative food intake for OXM1-37 became significantly lower 
than that for the saline control, yielding 12.3±2.8 % suppression (p<0.05) by day 8. In 
contrast, the cumulative body weight was shown to drop suddenly by 6.5±1.4 g on day 5 
for the animals receiving OXM1-37 at 0.50 mg/kg. On the other days, such a drop was not 
observed, and the body weight gained by an average of 3.0±0.9 g/day on day 6 and 
thereafter, which was slightly but insignificantly lower than 5.2±0.6 g/day for the saline 
control in the same period. Because of this body weight drop on day 5, the cumulative 
body weight gain with OXM1-37 administration at 0.50 mg/kg was shown to be reduced 
considerably by 62.3±9.1 % by day 8 (p<0.05). In a related context, Table 4.2 shows the 
daily water intake behavior between these two groups. It was shown coincidentally that 
the daily water intake in the animals receiving OXM1-37 was also decreased on day 5 by 
9.6±1.3 g. Moreover, the 4 h food intake suppression was inconsistent between day 1, 4 
and 7; suppression was significant on day 1 and 4 by 16.1±2.4 and 38.5±10.3 %, 
respectively, while no effect was observed on day 7, -4.6±11.7 %. Therefore, the food 
intake suppression was variable and thus, not a primary reason for the reduced body 
weight gain, when OXM1-37 was administered repeatedly on a daily basis. Rather, this 
effect on body weight was primarily due to the reduced water intake observed 
specifically on day 5. 
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Figure 4.3 shows the cumulative food intake at 2, 4, 6 and 24 h following single 
pulmonary administration of OXM30-37 and NAc-OXM30-37 at 0.10 mg/kg, compared to 
that of saline and OXM1-37 at 0.50 mg/kg. The latter comparator data were adopted from 
Figure 4.1. The doses of OXM30-37 and NAc-OXM30-37 (0.10 µmol/kg) were chosen to be 
equimolar to the effective dose of OXM1-37 (0.50 mg/kg), as seen in Figure 4.1. 
Unfortunately, neither of the “active” fragment peptides, OXM30-37 and NAc-OXM30-37 
caused significant food intake suppression at any time points, despite higher lung 
absorption expected for these lower molecular weight peptides. 
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Figure 4.2 Cumulative A) food intake and B) body weight gain during daily repeated orotracheal instillations of saline ( ; n=7) and 
OXM1-37 at 0.50 mg/kg ( ; n=6) for 7 days in freely feeding rats. Data represent mean±SE; * indicates p<0.05, compared 
to the corresponding values for the saline control, derived from the two-way ANOVA, followed by the unpaired t-test. 
 
 
 Table 4.2 Daily water intake during daily repeated orotracheal instillations of saline (n=7) and OXM1-37 at 0.50 mg/kg (n=6) for 
7 days in freely feeding rats. Data represent mean±SE. 
 
Group 
 
1 
 
2 
 
3 
Time (Days) 
   4 
 
5 
 
6 
 
7 
 
8 
  Saline 31.3±1.2 33.1±0.9 29.8±1.7 32.9±1.5 28.0±1.5 30.4±1.7  30.6±1.4 28.2±1.2  
  OXM1-37 29.9±1.7 30.0±1.2 31.3±2.2 28.9±1.6 19.3±0.5* 27.1±2.3 25.2±1.5 27.8±1.8 
* indicates p<0.05, compared to the saline control as derived from two-way ANOVA followed by the unpaired t-test.
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Figure 4.3 Cumulative food intake at 2, 4, 6 and 24 h following single orotracheal 
instillation of saline ( ; n=8), OXM1-37 at 0.50 mg/kg ( ; n=6), 
OXM30-37 at 0.10 mg/kg ( ; n=6) and NAc-OXM30-37 at 0.10 mg/kg  
( ; n=6) in freely feeding rats. Data represent mean±SE, * indicate 
p<0.05, compared to the corresponding values for the saline control, derived 
from the one-way ANOVA, followed by the Tukey’s test.  
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4.C.2   c-FOS EXPRESSION IN THE HYPOTHALAMUS AND BRAINSTEM 
FOLLOWING PULMONARY ADMINISTRATION OF OXM1-37        
Figure 4.4 shows the immunofluorescence micrographs of c-Fos specific 
expression in the hypothalamus (A) ARC and (B) PVN regions and the brainstem (C) AP 
region in each rat, taken at 4 h following single orotracheal instillation of saline and 
OXM1-37 at 0.50 mg/kg. These micrographs were analyzed to yield the bilateral and 
unilateral c-Fos positive pixel counts in the hypothalamus (ARC and PVN) and brainstem 
(AP) regions, respectively, as shown in Figure 4.5. The c-Fos expression in the 
hypothalamus ARC and the brainstem AP regions was considerably increased in response 
to OXM1-37 administration, compared to the saline control, represented by significant 2.4- 
and 2.0-fold increases in the c-Fos positive pixels, respectively. In contrast, the c-Fos 
expression in the hypothalamus PVN region remained low and statistically comparable 
between groups. These results suggested that the ~30 % food intake suppression by 
OXM1-37 in Figure 4.1 was apparently associated with this c-Fos increase in the 
hypothalamus ARC and brainstem AP, but not in the PVN.  
Likewise, Figure 4.6 shows the c-Fos expression at each of the brain regions at           
4 h following the 8th instillation of saline or OXM1-37 at 0.50 mg/kg in the repeated daily 
administration protocol. Consistent with the results from the single pulmonary 
administration (Figure 4.4), the c-Fos expression was substantially increased in the 
hypothalamus ARC and brainstem AP regions by OXM1-37, while no apparent changes 
were observed in the hypothalamus PVN region, compared to the saline control.  
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Figure 4.4 Immunofluorescence micrographs of the 30 µm thick coronal brain 
sections showing c-Fos specific expression in the right and left 
hypothalamus arcuate nucleus (ARC) in each rat (n=3), taken at 4 h 
following single orotracheal instillation of saline and OXM1-37 at 
0.50 mg/kg. The micrograph images were taken under 400X 
magnification, and the scale bars represent 50 µm. The rectangular 
boxes represent the area chosen for the c-Fos count in Figure 4.5. 
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 Figure 4.4 Immunofluorescence micrographs of the 30 µm thick coronal brain 
sections showing c-Fos specific expression in the right and left 
hypothalamus paraventricular nucleus (PVN) in each rat (n=3), taken 
at 4 h following single orotracheal instillation of saline and OXM1-37 at 
0.50 mg/kg. The micrograph images were taken under 400X 
magnification, and the scale bars represent 50 µm. The rectangular 
boxes represent the area chosen for the c-Fos count in Figure 4.5. 
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 Figure 4.4 Immunofluorescence micrographs of the 30 µm thick coronal 
brain sections showing c-Fos specific expression in the unilateral 
brainstem area postrema (AP) region in each rat (n=3), taken at 
4 h following single orotracheal instillation of saline and OXM1-37 
at 0.50 mg/kg. The micrograph images were taken under 400X 
magnification, and the scale bars represent 50 µm. The 
rectangular boxes represent the area chosen for the c-Fos count in 
Figure 4.5. 
C) AP 
 
AP 
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Figure 4.5 c-Fos positive pixel counts in the bilateral rectangular areas (488 X 720 
pixels) in the hypothalamus A) arcuate nucleus (ARC) and B) paraventricular 
nucleus (PVN) and the unilateral area of C) the brainstem area postrema (AP) 
region, taken at 4 h following single orotracheal instillation of saline and 
OXM1-37 at 0.50 mg/kg. Data represent mean±SE (n=3). * indicates p<0.05, 
compared to the corresponding values of the saline control animals, derived 
from the unpaired t-test. 
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Figure 4.6 Immunofluorescence micrographs of the 30 µm thick coronal brain sections showing c-Fos specific expression in the A) 
bilateral hypothalamus arcuate nucleus (ARC) and B) paraventricular nucleus (PVN) regions and C) the unilateral 
brainstem area postrema (AP) region in each rat, taken at 4 h following the 8th orotracheal instillation of saline and 
OXM1-37 at 0.50 mg/kg on day 8 of the repeated daily administration protocol. The micrograph images were taken under 
400 X magnification, and the scale bars represent 50 µm. The arrows indicate the hypothalamus ARC region. 
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4.D DISCUSSION  
 
 This chapter studied the effects of pulmonary administration of OXM on food 
intake suppression and reduced body weight gain in freely feeding rats, similar to 
Chapter 3 for PYY. As these two peptides are co-secreted postprandially, it was of 
interest to assess the potential of OXM for appetite suppression following pulmonary 
delivery, as much as PYY in Chapter 3. The food intake suppression by the endogenously 
secreted full length peptide, OXM1-37 appeared to be dose- and time-related, causing 
significant suppression at 0.50 mg/kg over 4-6 h (Figure 4.1). The daily pulmonary 
administration for 7 days enabled significant reduction of the body weight gain by 62.3 % 
(Figure 4.2). However, this effect on the body weight appeared to be more complex than 
PYY, as the food intake suppression was inconsistent on a daily basis and the water 
intake was considerably reduced only on day 5. Through the immunofluorescence brain 
microscopy, however, the food intake suppression by OXM1-37 on day 1 was shown to be 
accompanied with neuronal activation in the hypothalamus ARC and brainstem AP 
regions, as indicated by the increased c-Fos expression (Figures 4.4-4.6). Meanwhile, the 
“active” fragment peptides, OXM30-37 and NAc-OXM30-37 were ineffective in causing 
significant food intake suppression, despite their logically higher lung absorption by 
virtue of lower molecular weights (Figure 4.3).  
Pulmonary administration of OXM1-37 at 0.05-0.50 mg/kg showed dose-related 
and short-term food intake suppression, reaching the maximum effect by 30 % at 4 h. The 
literature also reported dose-proportional 28 to 50 % of food intake suppression by 
OXM1-37 at 0.01-0.40 mg/kg, when administered via intraperitoneal and 
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intracerebroventricular injections (Baggio et al., 2004; Dakin et al., 2001; Dakin et al., 
2004). However, the effects were shown to last for longer 8-12 h, which was different 
from the present study with pulmonary administration.  
The daily repeated pulmonary administration of OXM1-37 for 7 days at 0.50 mg/kg 
significantly reduced the body weight gain by 62 % at the end of the study (Figure 4.2). 
However, this appeared to be caused primarily by a sudden loss of the body weight on 
day 5 that coincided with a significant 31 % reduction in daily water intake (Figure 4.2 
and Table 4.2). This observation was further confounded by only slightly lower gain of 
body weight in the animals receiving OXM1-37 on other than day 5, compared to the 
saline control. Moreover, the 4 h food intake suppression seen on day 1 was not 
continued on day 4 and 7, showing variability and possibly tolerance to the suppression. 
At this point, while the exact cause of this inconsistent food intake suppression was 
uncertain, the reduced water intake by OXM1-37 was similarly reported in the literature. In 
rats, repeated twice-daily intraperitoneal and intracerebroventricular injections of 
OXM1-37 at 0.20 and 0.01 mg/kg, respectively, for 7 days demonstrated cumulative food 
intake suppression and reduced body weight gain by ~10 and ~44 %, respectively, at the 
end of the study (Dakin et al., 2002; Dakin et al., 2004). The intraperitoneal injection of 
OXM1-37 however, was shown to reduce body weight gain significantly, starting from day 
1, although the daily food intake suppression became significant only staring from day 4. 
Intriguingly, this was also accompanied with significant reduction of water intake on 
day 1 and 2 by ~14 %, while no effect was observed on the subsequent days (Dakin et al., 
2004). Clearly, although the changes of food and water intake were different from those 
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in the present study, it was equally observed that the long-term effect on body weight was 
a consequence of transient food and water intake suppression during the repeated dosing 
period. Unfortunately, the exact cause for this reduced water intake by OXM1-37 has yet 
to be clarified. Meanwhile, this effect on body weight with OXM1-37 may have also 
resulted from increased energy expenditure and reduced adiposity (Dakin et al., 2002). 
As such a contribution could not be ruled out, it is a subject for further clarification.  
Immunofluorescence microscopic c-Fos evaluation within the brain demonstrated 
that pulmonary administration of OXM1-37 increased its expression in the hypothalamus 
ARC and brainstem AP regions, but not in the PVN region (Figures 4.4-4.6). This was 
consistent with the literature employing intraperitoneal injection (Dakin et al., 2004). 
While this increased c-Fos expression in response to OXM1-37 could reflect activation of 
certain unknown neuroendocrine mechanisms in the brain, a strong advocate was direct 
interaction with the GLP-1 receptors (Baggio et al., 2004; Druce et al., 2009). 
Supportively, in the GLP-1 receptor knock-out mice, intraperitoneal injection of OXM1-37 
failed to cause food intake suppression (Baggio et al., 2004; Schepp et al., 1996). 
Moreover, the GLP-1 receptor antagonism by intra-arcuate, intraparaventricular or 
intracerebroventricular injection of exendin9-39 diminished appetite suppression of 
centrally and peripherally injected OXM1-37 (Dakin et al., 2001; Dakin et al., 2004). 
Therefore, it can be implied that the increased c-Fos expression in response to pulmonary 
administration of OXM1-37 in this study was also related to its interaction with the GLP-1 
receptors. Even so, the increased c-Fos expression in the AP region could also be 
mediated by the indirect vagal pathway, which has however been inconsistent in the 
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literature (Chaudhri et al., 2006; Dakin et al., 2001; Dakin et al., 2004). Finally, it is 
noteworthy to point out that the brainstem region was shown to play a role in controlling 
thirst homeostasis, and c-Fos activation was observed when water intake was reduced in 
response to certain stimuli (Johnson and Thunhorst, 1997; Salter-Venzon and Watts, 
2008). However, the data in the present study were insufficient to address this 
association, as the water intake reduction was only observed on day 5 and not on other 
days. 
The C-terminal octapeptide, OXM30-37 was chosen, by virtue of its inhibitory 
activity on gastric acid secretion in rodent models (Carles-Bonnet et al., 1991; Jarrousse 
et al., 1985; Jarrousse et al., 1986). In addition, its N-terminal acetylation was shown to 
protect the peptide from its N-terminal metabolism, resulting in 3-fold increased potency 
than OXM30-37 (Carles-Bonnet et al., 1992). However, this potency was still 30-fold less 
than the full length peptide, OXM1-37 (Carles-Bonnet et al., 1991; Carles-Bonnet et al 
1992; Jarrousse et al., 1986; Jarrousse et al., 1985), despite substantially lower molecular 
weights (from 4425 Da to 957.1 or 999.3 Da) expected to yield higher lung absorption. 
Unfortunately, this appeared not to be the case in this study, as no food intake 
suppression was observed for both of these fragment peptides, when administered at the 
dose equimolar to the effective dose of OXM1-37 i.e., 0.50 mg/kg. This happened to be 
consistent with the most recent study, published after this study, where the GLP-1 
receptor affinity of OXM30-37 was almost negligible, compared to OMX1-37, and the 
peptide was enzymatically degraded by DPPIV and NEP (Druce et al., 2009). Therefore, 
it was reasonable in this study that the faster lung absorption expected for these fragment 
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peptides was unable to overcome their substantially lower receptor affinities and marked 
susceptibility to metabolic degradation.  
Through the studies in Chapters 3 and 4, there were clear differences in the 
pharmacological response and target brain regions between PYY3-36 and OXM1-37. First, 
the dose-responses were different. At 0.10 µmol/kg, while PYY3-36 (0.40 mg/kg) was 
ineffective, OXM1-37, at 0.50 mg/kg caused significant 30 % food intake suppression. 
Hence, OXM1-37 was more potent than PYY3-36 in causing the food intake suppression 
following pulmonary administration. In contrast, intraperitoneal injection was shown to 
require a rather higher dose for OXM1-37 than PYY3-36 to yield comparable food intake 
suppression in rats (30 nmol/kg (0.10 mg/kg) vs. 1 nmol/kg (0.004 mg/kg), respectively; 
Batterham et al., 2002; Dakin et al., 2004). Therefore, this observation of potency could 
be only specific to pulmonary administration. Secondly, OXM1-37 appeared to cause 
transient, yet significantly reduced water intake, which was not the case for PYY3-36 at 
all. Thirdly, pulmonary administration of PYY3-36 was shown to increase the c-Fos 
expression exclusively in the hypothalamus ARC region, while that of OXM1-37 caused 
its activation in the brainstem AP region, in addition to the hypothalamus ARC region. 
Therefore, this implied the role of vagal afferent stimulation in OXM’s food intake 
suppression in addition to its action on the central nervous system, as observed with 
PYY3-36. 
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4.E CONCLUSIONS 
Pulmonary administration of OXM1-37 at 0.50 mg/kg was shown to cause 
significant 4-6 h food intake suppression in rats, and its repeated administration resulted 
in 62 % reduction in the body weight gain by day 8. However, unlike PYY, this effect on 
the body weight gain was not simply caused by continued and consistent food intake 
suppression on a daily basis, but could have been associated with the reduced water 
intake observed only on day 5. Even so, the food intake suppression was associated with 
the neuronal activation, represented by the increased c-Fos expression in the  
hypothalamus ARC and brainstem AP regions, suggesting the involvement of both the 
central nervous system control and vagal stimulation for its action. Unfortunately, the 
short “active” fragment peptides, OXM30-37 and NAc-OXM30-37 failed to cause food 
intake suppression, presumably due to their lower affinities to the currently proposed 
target receptors, GLP-1 receptors, along with the susceptibility to metabolic degradation. 
Overall, this chapter served as a preliminary attempt to seek for effective appetite 
suppression following pulmonary administration of OXM1-37 by the mechanisms 
differing from those for PYY3-36 (Chapter 3). Clearly, further studies are essential to 
demonstrate the proof-of-concept for the application of OXM in the obesity treatment.  
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CHAPTER 5 
 
IN VIVO PHARMACOKINETICS OF PULMONARY            
PYY3-36 IN RATS: COMPARATIVE ASSESSMENT WITH 
OTHER PEPTIDES 
 
 
5.A INTRODUCTION 
 
 In Chapters 3 and 4, pulmonary delivery of PYY and OXM was shown to cause 
significant food intake suppression and reduced body weight gain, yet at relatively higher 
doses than those reported to be effective following intravenous or intraperitoneal 
injection. While this implied moderate-to-low lung absorption and bioavailability for 
these 4 kDa peptides, it was uncertain as to the rate and extent of lung absorption for the 
plasma concentration profiles. Such information is critical to understand how both 
peptides exhibited only 4-6 h food intake suppression following pulmonary 
administration (Figure 3.2 and 4.1). Accordingly, in this chapter, the lung disposition 
kinetics and pharmacokinetics were characterized for PYY3-36, as one of the effective 
anorectic gut secreted peptides in this project, following intratracheal instillation in rats. 
A sensitive enzyme immunoassay was first validated for PYY3-36 determination in rat 
plasma and then, employed to determine the plasma concentration-time profiles 
following intratracheal instillation and intravenous injection. While these were analyzed 
by the conventional noncompartmental analysis to determine the absolute bioavailability, 
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a novel lung disposition kinetic model was developed and applied to derive the 
rate constants for lung absorption and non-absorptive loss. This new model was also 
applied to the in-house or literature plasma concentration-time profile data for other 4-6 
kDa peptides similarly administered to the rat lungs, in order to comparably assess their 
lung disposition kinetics. 
5.B MATERIALS AND METHODS 
 
5.B.1 MATERIALS  
 
 Lyophilized human PYY3-36 (molecular weight of 4050 Da) was purchased from 
Phoenix Pharmaceuticals, Inc. (Burlingame, CA). It was received as a lyophilized 
powder, certified to contain 100 % of the peptide; therefore, this was directly 
reconstituted to prepare PYY dosing solutions. Phosphate-buffered saline (PBS) at 0.2 M 
was obtained from Invitrogen Corporation (Carlsbad, CA). 
 
5.B.2 ANIMALS 
This research adhered to the NIH Principles of Laboratory Animal Care (NIH 
publication # 85-23, revised in 1985), and its protocol was approved by the VCU IACUC 
(AM10038). Sprague-Dawley rats (Male; Hilltop Lab Animals Inc., Scottdale, PA) 
weighing 300-350 g were used following ≥ 2 days of acclimatization at the animal care 
facility. All animals had free access to standard rat chow (Harlan Teklad Global Diet, 
Product # 7012, Boston, MA) and tap water throughout. 
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5.B.3 DETERMINATION OF PYY3-36 IN RAT PLASMA BY ELISA 
          The total human PYY ELISA kits in the 96 well strip plate format were purchased 
from Millipore Corporation (Billerica, MA). These kits were used according to the 
manufacturer’s protocol following validation for the use of rat plasma samples, as they 
had been validated only for the use of human plasma or serum. The manufacturer had 
shown that the kits equally recognize PYY1-36 and PYY3-36, but porcine PYY only by 1 % 
(Millipore Corporation). Correspondingly, our assay validation ensured negligible cross-
reactivity with rat PYY (data not shown), as porcine and rat PYY share the identical 
amino acid sequence (Grandt et al., 1994). As a result, the endogenous immunoreactive 
PYY concentrations in plasma from untreated rats were shown to be negligible at any 
time points (data not shown). 
5.B.3.a   THEORY  
 
         Figure 5.1 shows a schematic diagram of the solid phase sandwich- ELISA for PYY 
determination used in this study. The assay employs two polyclonal rabbit anti-human 
PYY antibodies (Abs), i.e., untagged and biotinylated Abs, sandwiching PYY molecules 
via two distinct epitope sites. At one end, PYY molecules are captured by the untagged 
PYY Abs, followed by immobilization to the wells via pre-coated anti-rabbit IgG Abs 
(steps 1 and 2). Simultaneously, on the other end, the biotinylated anti-PYY Abs bind the 
PYY molecules, completing the sandwich formation (step 2). Unbound Abs are removed 
by washing (step 3), while subsequent incubation with streptavidin-horseraddish 
peroxidase (SA-HRP) enables it’s binding with biotin on the biotinylated Abs (step 4). 
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The enzyme (HRP) then reacts with the substrate, 3,3’,5,5,’-tetra-methylbenzidine 
(TMB), enabling spectrophotometric detection at 450 nm (step 5).  
 
 
Figure 5.1 A schematic diagram of the total human PYY ELISA kit (Millipore 
Corporation).  
 
 
5.B.3.b   ASSAY VALIDATION 
 
This total PYY ELISA was carried out, according to the protocol provided by the 
manufacturer (Appendix 3), yet validated by constructing the calibration curves in 
different matrices (proprietary plasma and rat plasma). The optical density (OD) values 
(Y) versus PYY concentrations (X) in a range of 0.1-4.0 ng/ml were plotted on a semi-
log scale, fitted to the following 4-parameter log-logistic equation: 
= untagged rabbit anti-human PYY antibody 
+ TMB  
+ 0.3 M HCl 
Wash  Measure 
Optical Density  
450/590 nm 
 
 
= biotinylated rabbit anti-human PYY antibody 
= anti-rabbit IgG antibody 
Step 1 Step 2 
Step 4   Step 5 
Wash  
Step 3 
TMB – 3,3’,5,5’-tetramethylbenzidine 
= PYY molecule 
Key: 
E = SA-HRP 
E E E E 
E E E 
E E E E 
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 Y = [A – D] / [1 + (log X/log C) ^ B] + D                                      (Eq. 5.1) 
where A and D are the maximum and minimum OD values, while B and C are the Hill 
slope and half maximal binding concentration, respectively.  
            The matrix effects were assessed by comparing the calibration curves of PYY3-36 
in 0.1, 1.0 and 10.0 % rat plasma diluted with PBS and those in the proprietary matrix 
provided by the kit. For validation, heparinized blood was withdrawn via cardiac 
puncture from three untreated rats under the anesthesia with sodium pentobarbital at 
50 mg/kg and pooled as the blank plasma following centrifugation at 3000 rpm for 3 min 
(Eppendorf centrifuge 5810R; Westbury, NY). Generally, ~10 ml blood was obtained 
from each rat, yielding ~5 ml of plasma. PYY3-36 was spiked into this blank rat plasma to 
prepare the standards at various known concentrations. These were further diluted with 
0.2 M PBS by 1000- 100- and 10-times to prepare the assay standards in 0.1, 1.0 and 
10.0 % rat plasma, respectively. The data were compared statistically with the analysis of 
covariance (ANCOVA) using JMP® (SAS Institute Inc., Cary, NC). 
Because the 10.0 % rat plasma standards caused the largest deviations from the 
manufacturer’s standards as later shown in Figure 5.3, the assay accuracy and precision 
were determined using the quality control (QC) samples of PYY3-36 prepared at 0.5, 1.0, 
2.0 and 3.0 ng/ml, in this matrix. These were calculated as % difference from the nominal 
concentration (% DFN) and % relative standard deviation (% RSD) from the triplicate 
measurements, respectively, using the below equations:  
 % DFN = │CQC-CNOM│/ CNOM x 100                                              (Eq. 5.2) 
 % RSD = standard deviation/mean x 100                                        (Eq. 5.3) 
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where CQC and CNOM are the measured and nominal PYY3-36 concentrations, respectively. 
 
5.B.4 IN VIVO PHARMACOKINETICS OF PYY3-36 FOLLOWING INTRAVENOUS   
INJECTION AND PULMONARY ADMINISTRATION 
        Rats were anesthetized with an intraperitoneal injection of sodium pentobarbital at 
50 mg/kg and placed on the surgical board in a supine position. For intravenous (IV) 
injection, 50 µl of PYY3-36 in saline was directly injected to the right jugular vein at  
0.08 mg/kg. An aliquot (0.1 ml) of the blood was withdrawn from the left jugular vein at 
0, 2, 10, 15, 20, 30, 45, 60, 90 and 120 min following injection. In contrast, pulmonary 
administration employed 60 µl intratracheal instillation of PYY3-36 in saline, as described 
in Chapter 3. Briefly, under the anesthesia, the trachea was surgically exposed, and 
the PYY3-36 solution was directly instilled into the tracheal lumen at 0.08 or 0.80 mg/kg, 
while the animal was inclined on the surgical board at 30ο. An aliquot (0.1 ml) of the 
blood was withdrawn from the jugular vein at 0, 5, 10, 20, 30, 45, 60, 90 and 120 min 
following instillation. During these experiments, the depth of anesthesia was carefully 
monitored, and supplemental pentobarbital was injected at 25 mg/kg as needed, while the 
body temperature was maintained under the heating lamp. All blood samples were 
immediately centrifuged at 12,000 rpm for 30 sec to collect the plasma samples; these 
were stored at -70 οC, until ELISA analysis. For determination of PYY3-36 concentrations, 
these samples were diluted in 0.1, 1.0 or 10.0 % of rat plasma matrix and analyzed using  
the matrix matched PYY3-36 standard curves. 
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5.B.5  PHARMACOKINETIC DATA ANALYSIS 
5.B.5.a   NONCOMPARTMENTAL ANALYSIS  
The plasma concentration-time profile of PYY3-36 following intravenous injection 
 
or intratracheal instillation from each animal was first analyzed by the conventional 
noncompartmental analysis. The peak plasma concentration (Cmax) and the time required 
to reach Cmax (Tmax) were visually derived from each profile, while the other parameters 
were computed using WinNonlin version 5.0 (Pharsight Corp., Mountain view, CA). The 
terminal half-life (t1/2), area under the plasma concentration-time curve (AUC0-inf), 
apparent clearance (CL/F) and apparent pseudo-steady state volume of distribution 
(Vpss/F) were calculated from the below equations: 
t1/2 = 0.693/β                                                                                                 (Eq. 5.4) 
 
where β represents the slope of the terminal phase on the plasma 
concentration-time profile on a semi-log plot, via linear regression. 
AUC0-inf  = AUC0-tlast + AUCtlast -inf                                                                                           (Eq. 5.5) 
 
where AUC0-t and AUCt-inf , respectively, are calculated by the trapezoidal method 
using the profile data between t=0 and the last sampling point, tlast and by Clast/β where 
Clast is the plasma concentration at time tlast.                                                                   
CL/F = Dose/AUC0-inf                                                                                  (Eq. 5.6) 
 
Vpss/F = (CL/F)/β                                                                                         (Eq. 5.7) 
The absolute bioavailability (a fraction), F, following intratracheal instillation (IT) was 
calculated for individual profiles relative to the mean AUC0-inf following intravenous 
injection (IV) with dose normalization, as shown below: 
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F = [AUCIT/ AUCIV] x [DoseIV/ DoseIT]                                                     (Eq. 5.8) 
 
The derived parameters were expressed as mean±standard deviation (SD) across animals 
and compared statistically using the unpaired t-test where p<0.05 was considered to be 
significant. 
 In addition, the initial volume of distribution was also calculated following 
intravenous injection using the equation: 
Vcc = Dose/Co                                                                                              (Eq. 5.9) 
 
where Co is the extrapolated concentration at time zero on the plasma concentration-time 
profiles. 
5.B.5.b   NOVEL COMPARTMENTAL KINETIC MODEL ANALYSIS 
 
 Figure 5.2 shows a lung disposition kinetic model integrating two compartment 
systemic disposition, which was used to derive the rate constants for lung absorption (ka) 
and non-absorptive loss (knal) for PYY3-36 following intratracheal instillation. As later 
seen in Figure 5.4, the intravenous injection profile of PYY3-36 appeared to be described 
by the two compartment model with the first-order rate constants for distribution and 
elimination, k12, k21 and k10. In contrast, the lung disposition was modeled, assuming 
parallel absorption and non-absorptive loss with their respective first-order rate constants, 
ka and knal. No absorption was assumed from the gastrointestinal (GI) tract due to its 
macromolecular peptidic nature. As previously suggested (Pang, 2004; Sakagami et al., 
2002), this lung’s non-absorptive loss could be due to mucociliary clearance, local 
metabolic degradation and/or phagocytosis, although it was not feasible to separately 
derive each of these rate constants through this modeling analysis. 
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 In order to derive the systemic disposition parameter values for k12, k21, k10, Vdcc 
and Vdpc, the mean plasma concentration-time profile of PYY3-36 following intravenous 
injection was analyzed by the curve-stripping method, assuming the two-compartment 
model (i.e., the model omitting the lung compartment from Figure 5.2; Gibaldi, 1982). 
These values were then fixed, when the mean plasma concentration-plasma profiles of 
PYY3-36 following intratracheal instillation were fitted to the kinetic model shown in 
Figure 5.2 via nonlinear least square regression analysis using Scientist® for Windows 
(Micromath Research, St. Louis, MO). This curve-fitting employed numerical integration 
of the differential equations describing the model. As a result, the lung disposition rate 
constants, ka and knal, were derived as the best parameter estimates at each of the PYY3-36 
doses. From the model shown in Figure 5.2, the rates of change in the amount of PYY3-36 
in the lung (ML), central (MC) and peripheral (MP) compartments were described as 
follows: 
               d(ML)/dt = - (ka + knal) x ML                                                                  (Eq. 5.10) 
               d(MC)/dt = ka x ML – (k12 + k10) x MC + k21 x MP                               (Eq. 5.11) 
               d(MP)/dt = k12 x MC - k21 x MP                                                             (Eq. 5.12) 
Initial conditions at t=0 were: 
 ML = Dose 
 MC = 0 
 MP = 0 
 
The “goodness-of-fit” parameters including the model selection criteria (MSC) and 
coefficient of determination (COD) were generated by Scientist®, while the model fit was 
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also assessed by visual inspection of all residuals and 95 % confidence intervals (CIs) of 
the derived parameter estimates. In Appendix 4, the Scientist® (model, data and 
parameter) files, plot and statistical output for the ka and knal values for PYY3-36 at 
0.08 mg/kg following intratracheal instillation are shown as an example. After successful 
curve-fitting was ensured, the best parameter estimates for ka and knal were used to 
calculate the absolute bioavailability, F, from the following equation: 
 F= ka / (ka + knal)                                                                                         (Eq.5.13) 
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Figure 5.2 Lung disposition kinetic model for PYY3-36 and other peptides administered to 
the lung for systemic absorption in rats. No absorption was assumed from the 
gastrointestinal (GI) tract. 
                   Keys: ka, first-order rate constant for lung absorption; knal, first-order rate 
constant for non-absorptive loss in the lung; k12 and k21, intercompartmental 
distribution rate constants; k10, systemic elimination rate constant; Vdcc and 
Vdpc, central and peripheral compartment volumes, respectively. 
ka 
Dose 
Lung 
Central compartment 
(Vdcc) 
knal 
k10 
k12 
k21 
Peripheral compartment 
(Vdpc) 
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5.B.6 LUNG DISPOSITION KINETICS OF OTHER 4-6 kDa PEPTIDES 
FOLLOWING PULMONARY ADMINISTRATION IN RATS 
          To assess the lung disposition kinetics of other 4-6 kDa peptides administered to 
the lungs in rats, the literature and in-house data were searched. Accurate and reliable 
plasma concentration-time profiles for three peptides following intravenous injection and 
intratracheal instillation in rats were used, as shown in Table 5.1; PYY is also shown. 
Incidentally, all of these peptides, exenatide, human parathyroid hormone (PTH1-34) and 
human insulin appeared to undergo two-compartmental systemic disposition like PYY, as 
later shown in Figure 5.7. Therefore, the curve-stripping method was applied for deriving 
the parameters as shown in Table 5.1. Each of the profile data following pulmonary 
administration was then extracted into a spreadsheet and fitted to the kinetic model 
shown in Figure 5.2 to derive the best ka and knal values through the nonlinear curve-
fitting using Scientist®, as described in the previous section, while the systemic 
disposition parameters shown in Table 5.1 were fixed throughout. 
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Table 5.1 Four peptides, their molecular weights and doses tested for intravenous injection in rats, published in the literature or 
obtained in-house alongside their systemic disposition parameters derived from the curve-stripping method. 
Peptides 
Molecular 
weight 
(Da) 
Dose 
(mg/kg) 
Systemic parameters 
 k12      k21     k10          Vdcc     Vdpc   
        (min-1)                     (ml) Reference 
Peptide YY (PYY3-36) 4050 0.08 0.02    0.09   0.03      27.7     5.9 Present Study 
Exenatide  4187 0.60 0.01   0.02   0.07      64.8    50.7 Gedulin et al., 2008 
Human parathyroid hormone (PTH1-34) 4278 0.08 0.02   0.04   0.09       57.7   32.1 Patton et al., 1994 
Human insulin  5808 0.004 0.06   0.10    0.30       57.7   31.3    unpublished in-house data 
100
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5.C RESULTS AND DISCUSSION 
 
5.C.1 ELISA VALIDATION FOR PYY3-36 DETERMINATION IN RAT PLASMA 
 
As recommended by the manufacturer, the 4 parameter log-logistic equation was 
shown to best fit the OD values at various PYY3-36 concentrations of the calibration 
standards in all matrices. Figure 5.3 (A) shows such standard curves generated using the 
PYY3-36 standards in 10-, 100- and 1000-times diluted rat plasma, compared to the curve 
generated using the standards provided by the kit. While each of the standard curves 
yielded an excellent fitting coefficient of ≥ 0.98, these were significantly different 
(p<0.05, ANCOVA) and, at given concentrations, the OD values were lower in the rat 
plasma standards. While this demonstrated the assay interference from the rat plasma 
matrix, an excellent correlation of each standard curve reasonably suggested that 
quantitative determination of PYY3-36 concentration was still feasible using the matrix-
matched standards. Accordingly, Table 5.2 shows the assay accuracy (% DFN) and 
precision (% RSD) for the PYY3-36 QC samples at 0.5-3.0 ng/ml in the 10-times diluted 
rat plasma. The % DFN and % RSD were ≤ 11.5 % and ≤ 12.3 %, respectively, both of 
which were within the recommended acceptance limits (20 %) for quantitative 
immunoassays in biopharmaceutical analysis (Smolec et al., 2005). From this validation, 
0.5 ng/ml was the lowest assay concentration for quantitation and therefore, 5.0 ng/ml 
was the lowest plasma concentration, given the minimum dilution factor of 10-times in 
this assay. In contrast, the higher PYY3-36 concentrations could be determined using 100- 
or 1000-times dilution scheme in both the samples and the standards.  
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Figure 5.3 Calibration curves for PYY3-36, in the standard samples containing (   ; n= 3) 
10-, (   ; n=4) 100- and (   ; n= 3) 1000-times diluted rat plasma with 0.2 M 
PBS, compared to the curve generated using the manufacturer’s standards in 
the proprietary plasma ( ; n=2). Data represent mean±SD except the 
manufacturer’s kit standard. The lines are the results of the 4 parameter log-
logistic curve-fitting.  
 
 
Table 5.2 Assay accuracy and precision determined at 0.5, 1.0, 2.0 and 3.0 ng/ml of 
PYY3-36 in the quality control (QC) samples (n=3) prepared by 10-times 
dilution of rat plasma with 0.2 M PBS. 
Nominal concentration (ng/ml) 0.5 1.0 2.0 3.0 
Accuracy (% DFN) 10.5 5.8           3.1         11.5 
Precision (% RSD) 12.3 0.4 4.2            4.8          
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 This kit (Millipore Corporation) was chosen following our preliminary validation 
of other kits. Table 5.3 summarizes the ELISA systems available commercially and their 
validation results. The sandwich ELISA from Millipore showed clear advantages with 
respect to negligible cross-reactivity with rat PYY and wider validated assay range over 
the other kits. However, no kits were shown to allow direct use of rat plasma for 
quantitation due to matrix effects.  
Table 5.3 Commercially available ELISA kits for PYY determination tested in this study. 
Manufacturer Assay 
principle 
Cross-reactivity 
with rat PYY [%] 
Validated 
assay range 
(ng/ml) 
Assay 
duration 
(h) 
Millipore Corporation sandwich 1 0.50-3.00 5.0 
Bachem Americas, Inc. competitive 100 0.25-1.00 5.0 
Phoenix 
Pharmaceuticals, Inc. 
competitive 5 0.25-0.80 4.5 
 
5.C.2 NONCOMPARTMENTAL ANALYSIS OF PYY3-36 PLASMA PROFILES 
FOLLOWING INTRAVENOUS AND PULMONARY ADMINISTRATION 
         Figure 5.4 shows the plasma concentration-time profiles of PYY3-36 following 
intravenous injection at 0.08 mg/kg and intratracheal instillation at 0.08 and 0.80 mg/kg 
on (A) linear and (B) semi-log scales. The pharmacokinetic parameters derived from the 
noncompartmental analysis are also shown in Table 5.4. The intravenous profile of 
PYY3-36 on the semi-log scale (B) was better described by biexponential equation than by  
monoexponential, suggesting its simultaneous distribution and elimination. Its terminal 
half-life was 26.1±1.9 min, while the CL and Vdpss values were calculated to be 
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1.0±0.04 ml/min and 36.1±4.1 ml, respectively.  In rats weighing 300 g, the plasma 
volume and the glomerular filtration rate were reported to be ~16.0 ml and 1.5 ml/min, 
respectively (Davies and Morris, 1993). Therefore, these data suggested that PYY3-36 was 
distributed to more than the plasma compartment and eliminated primarily by the kidney. 
In fact, PYY3-36 was shown to exhibit low hepatic extraction (~22 %) in the isolated 
perfused rat liver model (Beckh et al., 1992). 
 At the identical dose of 0.08 mg/kg, the plasma PYY3-36 concentrations following 
intratracheal instillation were substantially lower than those following intravenous 
injection (Figure 5.4). This demonstrated a low bioavailability of pulmonary PYY3-36, 
yielding a F value of 0.14±0.01. While this implied a slow rate of lung absorption due to 
its large 4 kDa molecular weight, the slope of the terminal phase (β) and half-life (t1/2) 
were statistically consistent with those following intravenous injection (p>0.05; 
Figure 5.4 and Table 5.4). This suggested that the lung absorption was not a kinetically 
rate-determining process and the systemic elimination was still the slowest following 
intratracheal instillation, i.e., non “flip-flop” in pharmacokinetics. The plasma PYY3-36 
concentrations following intratracheal instillation at the 10-fold higher dose of 
0.80 mg/kg increased almost proportionately, and the bioavailability (F) remained 
consistent, yielding 0.12±0.03. This suggested the linear pharmacokinetics for PYY3-36 
within this dose range, also confirmed by their consistent dose-normalized AUC0-inf and 
Cmax (Table 5.4). 
 As shown in Chapter 3 (Figure 3.2), the intratracheal instillation of PYY3-36 at 
0.80 mg/kg caused significant food intake suppression over a short period of 4-6 h, while 
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the lower doses at 0.40 and 0.08 mg/kg were ineffective. At this effective 0.80 mg/kg 
dose, the PYY3-36 concentrations in plasma ranged between 41.8 and 726.3 ng/ml during 
the 2 h period, while those after 2 h were lower than 5.0 ng/ml (i.e., LOQ). This indicated 
a short systemic residence for this peptide in line with its short 4-6 h duration of action. 
Notably, these concentrations following intratracheal instillation far exceeded the 
endogenous postprandial concentrations at 0.6 ng/ml (160 pM) in rats (Jin et al., 1993). 
Therefore, superphysiological concentrations appeared to be necessary for this appetite 
suppression with PYY3-36 administered to the lung. 
 106 
 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Immunoreactive PYY concentration in plasma vs. time profiles following 
intravenous injection at 0.08 mg/kg (   ; n=3) and intratracheal instillation at 
0.08 mg/kg (   ; n=4) and 0.80 mg/kg (   ; n=4) in rats on A) linear and B) 
semi-log scales. Data represent mean±SD. The solid lines are plotted by 
linear interpolation.  
                   Note that the intravenous profile has one missing value at 15 min and the 
intratracheal profile at 0.80 mg/kg has a missing value at 30 and 120 min. 
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Table 5.4 Noncompartmental pharmacokinetic parameters for PYY3-36 following 
intravenous injection at 0.08 mg/kg and intratracheal instillation at 0.08 and 
0.80 mg/kg in rats. 
Parameters 
Intravenous 
injection 
Intratracheal  
instillation  
Dose per body weight (mg/kg) 0.08 0.08 0.80 
Dose (ng) 24,000 24,000 240,000 
Co or Cmax (ng/ml) 855.3±192.4 75.0±9.3 726.3±69.0 
Tmax (min) 2.0±0.0 10.0±0.0 8.8±2.5 
AUC0-inf (ng x min/ml) 23861±1203 3353±259 29127±8336 
 β (min-1) 0.03±0.002 0.03±0.01 0.02±0.003 
t ½ (min) 26.1±1.9 25.5±9.0 32.6±4.0 
CL (ml/min)/F 1.0±0.04 6.4±1.4 8.2±2.8 
Vdcc (ml) 29.0±6.0 - - 
Vdpss (ml)/F 36.1±4.1 365.6±130.0 378.5±113.5 
F 1.00±0.10 0.14±0.01 0.12±0.03 
Cmax/Dose (kg/ml) - 936.88±116.01 910.00±84.17 
AUC 0-inf/Dose (kg x min/ml) - 41912.57±3239.48 36048.62±9023.42 
All pharmacokinetic parameters represent mean±SD. 
5.C.3 KINETIC MODEL ANALYSIS FOR LUNG DISPOSITION OF PYY3-36 
FOLLOWING PULMONARY ADMINISTRATION 
           As shown in Figure 5.4 (B), the plasma concentration-time profile of PYY3-36 
following intravenous injection was biexponential, suggesting its kinetic control by two 
disposition compartments. Hence, the curve-stripping method was used, and the values 
for k12, k21, k10, Vdcc and Vdpc were derived, as shown in Table 5.1 and Figure 5.5 (A). 
Indeed, such parameter estimates successfully predicted the intravenous profile, as shown 
in Figure 5.5(B). Hence, subsequent analysis was carried out for the mean data of 
PYY3-36 following intratracheal instillation at 0.08 and 0.80 mg/kg using the model 
described in Figure 5.2. The best parameter estimates for lung disposition, ka and knal are 
shown in Table 5.5, and the profiles predicted from the estimates are drawn in Figure 5.6. 
At each dose, the model was well-fitted to the mean profiles, confirmed by the 
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“goodness-of-fit” parameters, MSC ≥ 3.52 and COD ≥ 0.981 (Table 5.5). The ka and knal 
values were derived with 95 % CIs of 0.02-0.04 and 0.13-0.30, respectively, as shown in 
Table 5.5. These overall demonstrated satisfactory model selection and curve-fitting of 
the profiles using this model.  
 The kinetic rate constants of lung absorption (ka) and non-absorptive loss (knal) for 
PYY3-36 at 0.08 mg/kg were 0.03 and 0.17 min-1, respectively (Table 5.5). These values 
were statistically consistent with the corresponding values at 0.80 mg/kg, in line with the 
linear pharmacokinetics for PYY3-36. This lung absorption of PYY3-36 was moderately 
fast, with a consistent half-life of 23.1 min at the two doses, which suggested passive 
diffusion. In contrast, the knal values for PYY3-36 were 5.6- and 7.3-fold greater than the 
ka values with only 3-4 min of the half-life. In fact, these knal values were considerably 
higher than those previously derived as the mucociliary clearance in the isolated perfused 
rat lung (~22 min; Sakagami, 2000). Hence, as was the case for insulin delivered to the 
lung, this non-absorptive loss was attributed to local lung metabolism (Pang et al., 2005; 
Sakagami, 2000; Taylor et al., 2004). In this context, it was shown that PYY3-36 was 
metabolized by neutral endopeptidase 24.11 (Medeiros and Turner, 1994) that exists in 
the cell membrane fractions of the alveolar epithelial cells, macrophages as well as lung 
lining fluid of the lung (Forbes et al., 1999; Funkhouser et al., 1991; Wall and Lanutti, 
1993). It can be implied therefore that such enzymatic degradation contributed to this fast 
non-absorptive loss of PYY3-36 within the lung. As a result, despite moderately fast lung 
absorption, PYY3-36 yielded low absolute bioavailability from 0.12 to 0.15, consistent 
with that derived by the noncompartmental analysis.  
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Figure 5.5 A) Two-compartment systemic disposition model and B) immunoreactive 
PYY concentration in plasma vs. time profile following single intravenous 
injection at 0.08 mg/kg in rats, predicted from the parameter estimates in the 
model shown in panel A). The data represent mean±SD (   ; n=3), identical to 
those shown in Figure 5.4. The line represents the predicted plasma 
concentration-time profile. 
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Figure 5.6 Immunoreactive PYY concentration in plasma vs. time profiles following 
intratracheal instillation at 0.08 mg/kg (  ) and 0.80 mg/kg (  ) in rats, 
predicted using the derived parameter estimates shown in Table 5.5. Data 
represent mean±SD. 
 
 
Table 5.5 The best parameter estimates of the first-order rate constants for the lung 
absorption (ka) and non-absorptive loss (knal) of PYY3-36 following 
intratracheal instillation at 0.08 and 0.80 mg/kg. 
                                Rate constants (min-1)                                 Goodness-of-fit 
Dose             ka         95 % CI               knal       95 % CI             MSC         COD 
(mg/kg) 
0.08            0.03       0.02-0.03              0.17       0.13-0.22             3.67        0.988 
 
0.80            0.03       0.02-0.04              0.22       0.14-0.30             3.52        0.981 
95 % CI: 95 % confidence interval; MSC: model selection criteria; COD: coefficient of determination 
MSC and COD were calculated by Scientist®. 
The ka and knal values between doses differed insignificantly based on their overlapping 95 % CIs. 
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5.C.4 LUNG DISOSITION KINETICS OF 4-6 kDa PEPTIDES FOLLOWING 
PULMONARY ADMINISTRATION IN RATS 
Figure 5.7 shows the plasma concentration versus time profiles for PYY3-36, 
exenatide, PTH1-34 and insulin following intravenous injection and intratracheal 
instillation in rats on a semi-log scale. Note that for a given peptide, the doses were either 
identical or different between the routes of administration, as shown in the legend. Like 
PYY, the terminal slopes for exenatide and PTH1-34 appeared to be consistent between 
intravenous injection and intratracheal instillation, while that for insulin was different, the 
latter demonstrating absorption rate-limited “flip-flop” kinetics. Each of the intravenous 
injection profiles was well predicted from the derived systemic disposition parameters 
shown in Table 5.1. While these were fixed, the plasma concentration-time data 
following pulmonary administration were fitted to the model shown in Figure 5.2. With 
the excellent fitting shown in Figure 5.7, the curve-fitting yielded 2.67-5.62 of MSC, 
0.961-0.998 of COD, and the ka and knal values were estimated, as summarized in 
Table 5.6. These results indicated appropriate model selection, excellent curve-fitting and 
reliable parameter estimates. 
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Figure 5.7 Plasma concentration vs. time profiles of PYY3-36, exenatide, PTH1-34, and 
insulin following intravenous injection (  ) and intratracheal instillation (  ) in 
rats. The data represent mean. The lines are the results of prediction using the 
parameter estimates derived from the curve-fitting. The intravenous and 
intratracheal instillation doses, respectively, were 0.08 and 0.80 mg/kg, 0.60 
and 0.60 mg/kg for exenatide, 0.08 and 0.30 mg/kg for PTH1-34 and 0.004 and 
0.03 mg/kg for insulin. 
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Table 5.6 The best parameter estimates of the first-order rate constants for lung absorption (ka) and non-absorptive loss (knal) 
for four 4-6 kDa peptides following intratracheal instillation in rats, and “goodness-of-fit” parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        95 % CI: 95 % confidence intervals, MSC: model selection criteria; COD: coefficient of determination.  
        MSC and COD were calculated by Scientist®. 
  
 
 
 
 
 
 
 
 
Peptide Molecular 
weight 
(Da) 
Dose 
(mg/kg) 
Rate constants  (min-1) 
ka          95 % CI               knal          95 % CI       
Goodness-of-fit 
MSC      COD 
PYY3-36 4050 0.80 0.03 0.020-0.040 0.22 3.52 0.981 
Exenatide 4187 0.60 0.003 0.002-0.003 0.02 3.74 0.983 
PTH1-34 4278 0.30 0.03 0.023-0.036 0.06 5.62 0.998 
Insulin 5808 0.03 0.002 0.001-0.002 0.03 
0.147-0.293 
0.015-0.020 
0.048-0.073 
0.019-0.051 2.67 0.961 
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The ka values for exenatide and insulin (0.003 and 0.002 min-1, respectively; 
Table 5.6) indicated their absorption half-lives of 231 and 347 min, respectively. In 
contrast, PYY3-36 and PTH1-34 exhibited 10-times faster absorption rate with much short 
half-life of 23 min. While the exact reason for such largely different ka values is 
unknown, the slow lung absorption rates for exenatide and insulin appeared to be 
consistent with their tendencies to form large molecular weight aggregates, respectively, 
at concentrations of the dosing solutions (Hudson et al., 2004; Pang, 2004; Pang et al., 
2007). For insulin, 0.1 mg/ml of its dosing solution used in this study was shown to 
contain ~40 % hexamers (Pang et al., 2007), such that the apparent molecular weight 
controlling diffusivity was 36 kDa, which should have a substantially slower rate of lung 
absorption than the monomeric insulin. Likewise, oligomer formation has been reported 
for exenatide above 0.01 mM (0.04 mg/ml) and so was at 7.0 mg/ml of its dosing solution 
used in Figure 5.7 (Gedulin et al., 2008; Hudson et al., 2004), although the molecular 
weight of these oligomers is presently unkown. In contrast, PYY3-36 and PTH1-34 were 
shown to exist as monomers at concentrations used in Figure 5.7. This accounted for the 
fast diffusive absorption of these peptides from the lung (Keire et al., 2000; Kamberi et 
al., 2005).  
The interpretation of the 10-times faster absorption rates for PYY3-36 and PTH1-34, 
compared to insulin and exenatide seemed to be only partly reasonable on the basis of 
molecular aggregates increasing their size. In the isolated perfused rat lung, the 
monomeric insulin yielded only twice faster absorption rate, compared to the hexameric 
species (0.004 and 0.002 min-1, respectively, Pang et al., 2007). Likewise, the apparent 
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tracheal permeability of monomeric insulin was demonstrated to be twice as much as its 
hexamers, which was in accord with the Stokes-Einstein’s principle for diffusion 
(Sakagami, 2003; Schanker and Hemberger, 1983). Therefore, the 10-times differences in 
the rate constants for lung absorption seen in Table 5.6 were unreasonably high, rather 
implying several other reasons for explanation. First, it was possible that the 
lung-regional distribution was different between studies. If peripheral lung deposition 
was achieved only for PYY3-36 and PTH1-34, faster absorption rates could be obtained, on 
the basis of higher alveolar epithelium permeability (Enna and Schanker, 1972; Pang et 
al., 2005; Sakagami, 2006). Secondly, it was possible that the molecular charge was 
different, affecting these ka values, like heparin that could be rapidly transported across 
the epithelial barrier than the rate predicted from diffusion (Qu et al., 2004). 
Meanwhile, the knal values for insulin and exenatide were larger and thus, yielded 
shorter half-lives of 23.1 and 34.7 min, respectively, while those for PYY3-36 and PTH1-34 
were much greater with the half-lives of 11.5 and 3.5 min, respectively. In most cases, 
these non-absorptive losses from the lung for peptides were attributed to local enzymatic 
metabolism by various lung peptidases in addition to mucociliary clearance (Forbes et al., 
1999; Pang et al., 2005; Sakagami et al., 2002). For example, insulin was shown to be 
metabolized by the lung ectopeptidase enzyme, aminopeptidase N (APN; Pang et al., 
2005), while PYY3-36 and PTH1-34 were highly susceptible to enzymatic metabolism by 
neutral endopeptidase 24.11 and chymotrysin, respectively, both of which are known to 
exist in the lung (Forbes et al., 1999; Medeiros and Turner, 1994; Yamaguchi et al., 
1988). However, the enzyme responsible for the metabolism of exenatide was not clearly 
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known (Copley et al., 2006). In this context, it was notable that the molecular aggregates 
of insulin were shown to be less favored for metabolic degradation, compared to the 
monomeric species (Pang et al., 2007). This in turn implied greater metabolic 
susceptibility of the monomeric PYY3-36 and PTH1-34, resulting in the rather higher rate 
constants of non-absorptive loss (Sakagami et al., 2002). 
 
5.D CONCLUSIONS 
              The in vivo pharmacokinetics of PYY3-36 was successfully determined following 
 
intravenous injection and intratracheal instillation in rats, deriving the kinetic descriptors 
for lung absorption and non-absorptive loss. Millipore’s human PYY ELISA kit was first 
validated to determine PYY3-36 concentrations in rat plasma. The plasma concentration-
time profiles of PYY3-36 were then determined and characterized with the conventional 
noncompartmental analysis. The profile for intravenous injection appeared to be 
biexponential, yielding the terminal t1/2 of 26.1±1.9 min. Its Vdpss and CL were 
36.1±4.1 ml and 1.0±0.1 ml/min, respectively, which suggested that the peptide was 
narrowly distributed within the body and likely eliminated via the kidneys. In contrast, 
the profiles for intratracheal instillation of PYY3-36 at 0.08 and 0.80 mg/kg exhibited 
dose-proportional Cmax and AUC0-inf, while the terminal slopes remained consistent with 
that seen in the intravenous profile. Therefore, its lung absorption kinetics were linear, 
controlled by diffusion, and not rate-determined in its overall pharmacokinetics, i.e., non 
“flip-flop”. Even so, the absolute bioavailability was shown to be only 12-14 %, and the 
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peptide virtually disappeared from the circulation within 2 h, which was reasonably 
consistent with its short (4-6 h) food intake suppression seen in Chapter 3.  
For its further assessment, the lung disposition kinetic model integrating absorption 
and non-absorptive loss was newly developed and applied to the profiles of PYY3-36 
following intratracheal instillation. The model was well-fitted to the profiles, successfully 
deriving the best parameter estimates of the first-order rate constants for lung absorption 
and non-absorptive loss, ka and knal, respectively. The ka and knal values for PYY3-36 were 
dose-independent, 0.03 and 0.17-0.22 min-1, respectively. It was suggested therefore that 
the lung absorption of PYY3-36 was moderately fast with the half-life of 23.1 min, which 
was competitively hampered by simultaneous non-absorptive processes such as  
metabolism and mucociliary clearance. This lung disposition kinetics of PYY3-36 was 
comparably assessed with those of other similar size peptides, exenatide, PTH1-34 and 
insulin, using this identical kinetic model to derive the ka and knal values. As a result, 
considerable differences were shown in the ka and knal values and thus in the lung 
disposition kinetics of these 4-6 kDa peptides, presumably caused by molecular aggregate 
formation, lung metabolism, mucociliary clearance and/or lung-regional distribution.  
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CHAPTER 6 
 
SUMMARY AND GENERAL CONCLUSIONS 
 
This dissertation project aimed to demonstrate that the lung can be exploited as a 
portal for delivering two anorectic gut secreted peptides, PYY and OXM, to the systemic 
circulation and then, to the brain, sufficient to exert food intake suppression and reduced 
body weight gain in freely feeding rats. The animal housing and experimental setup was 
carefully established to monitor food and water intake and body weight gain under 
physiological conditions and their changes in response to pulmonary administration of 
these peptides. Single pulmonary administration of the endogenously active PYY3-36 and 
OXM1-37 caused dose-related and transient food intake suppression between 4 and 6 h 
following administration. The maximum food intake suppression by PYY3-36 and           
OXM1-37 was 35.1±5.7 % and 30.0±5.4 % at 4 h, while requiring doses of 0.80 and 
0.50 mg/kg, respectively (Figures 3.2 and 4.1). Even so, their repeated pulmonary 
administration for 7 days successfully reduced body weight gain by 39.4±11.0 % and 
62.3±9.1 % by day 8, compared to the saline control (Figures 3.6 and 4.2). In contrast, 
neither of the “active” fragment peptides, i.e., PYY13-36, OXM30-37 and NAc-OXM30-37, 
was shown to be effective with this pulmonary delivery, when administered at the doses 
equimolar to those causing significant food intake suppression by PYY3-36 and OXM1-37, 
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i.e., 0.20 and 0.10 µmol/kg., respectively (Figures 3.5 and 4.2). This was presumably due 
to their lower molar potencies and rather greater metabolic susceptibility, compared to 
the endogenous peptides, even though their lung absorption was expected to be higher by 
virtue of lower molecular weights. Finally, the endogenously secreted form of PYY, 
PYY1-36 was shown to be equipotent to PYY3-36 following pulmonary administration, and 
intriguingly, this effect appeared to be sustained by 24 h. This was quite a contrast from 
the 10-fold lower activity of this peptide over PYY3-36 following intravenous injection 
(Chelikani et al., 2005), implying metabolic conversion of PYY1-36 to PYY3-36, 
presumably in the lung, and enabling prolonged systemic residence of PYY3-36 in the 
circulation.      
This food intake suppression with PYY was concurrent to the neuronal activation 
of c-Fos and reduced expression of orexigenic NPY in the hypothalamus arcuate nucleus 
(ARC) region (Figure 3.7 to 3.12). This provided a compelling evidence for the role of 
the central nervous system, while negligible c-Fos in the brainstem area postrema (AP) 
region suggested that the vagal afferent stimulation was not involved in the food intake 
suppression with pulmonary delivery of PYY. In contrast, the food intake suppression 
with pulmonary delivery of OXM1-37 was shown to be associated with neuronal activation 
(c-Fos) in the hypothalamus ARC and brainstem AP regions. This suggested the 
involvement of both the central nervous system control and vagal stimulation for the 
appetite suppression, although the water intake suppression emerged in the repeated 
dosing protocol (Table 4.2) confounded this deduction. 
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 The final chapter of this project was an attempt to kinetically characterize the 
lung absorption and disposition of PYY3-36 following pulmonary administration in rats. 
The PYY ELISA was fully validated for the use of rat plasma, so that the plasma 
concentration-time profiles following intravenous injection and intratracheal instillation 
were accurately determined. The intravenous injection profiles were biexponential, 
demonstrating simultaneous distribution and elimination (i.e., 2-compartments), while 
yielding the terminal half-life (t1/2) of 26.1±1.9 min. In contrast, the profiles following 
pulmonary administration of PYY3-36 at 0.08 and 0.80 mg/kg were dose-proportional and 
thus, linear kinetically. Moreover, their terminal t1/2 values were consistent with that for 
intravenous injection, which suggested non-“flip-flop” pharmacokinetics in rats. Even so, 
the absolute bioavailability (% F) remained low at 12-14 %, suggesting substantial non-
absorptive loss for this peptide from the lung. A new lung disposition kinetic model was 
developed by incorporating parallel lung absorption and non-absorptive loss. This model 
was then used to analyze the profiles following pulmonary administration to derive their 
rate constants, ka and knal, respectively, though nonlinear regression curve-fitting. The 
model was successfully fitted to each of the profiles, yielding the best parameter 
estimates for ka and knal at 0.03 and 0.17-0.22 min-1, respectively. While the dose-
independent ka values suggested passive diffusive lung absorption for this peptide, the 
knal values were 5-7 times greater than the ka values, as the kinetic evidence for the 
inefficient disposition in the lung, presumably via metabolic degradation. Finally, these 
ka and knal values for PYY3-36 were compared to those for other 4-6 kDa peptides 
administered to the rat lungs, i.e., exenatide, PTH1-34 and insulin. The absorption rate 
 121 
constants (ka) for exenatide and insulin were derived to be lower than those for PYY3-36 
and PTH1-34, as related to the tendency to form molecular aggregates for the former 
molecules. Nonetheless, several confounding factors were speculated to influence the 
absorption rate constants from the lung for these 4-6 kDa peptides. In contrast, the 
relatively slow non-absorptive losses (knal) for exenatide and insulin could be attributed to 
their limited lung enzymatic metabolism by virtue of aggregate formation, in contrast to 
the monomeric PYY3-36 and PTH1-34. Therefore, this comparative kinetic assessment 
showed considerable differences in the pulmonary disposition kinetics of these 4-6 kDa 
peptides administered to the lungs, influenced by the molecular aggregate formation and 
lung metabolism, alongside mucociliary clearance and/or lung-regional distribution.  
Overall, this dissertation project successfully provided the proof-of-concept in rats 
for needle-free delivery of the anorectic gut secreted peptides via the lung, potentially 
useful to control appetite and body weight in the obesity management. However, its 
extrapolation for clinical success is still challenging and probably premature. Apparently, 
appetite behavior and body weight change are substantially different between rodents and 
humans. Superphysiological systemic concentrations necessary with the exogenous 
administration of these gut secreted peptides have raised a concern of adverse responses, 
such as nausea and vomiting, while it remains uncertain if any compensatory responses 
arise during or upon termination of the treatment. Finally, the gut-brain axis for appetite 
control appears to be more complex involving several other peptides, in addition to the 
two peptides studies in this project. Nevertheless, favorable to the present study of 
pulmonary delivery, the doses of PYY3-36 and OXM1-37 required to suppress the food 
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intake or appetite have been reported to be considerably higher in rodents than humans 
(Batterham et al., 2003; Cohen et al., 2003; Degen et al., 2005; Druce et al., 2009; Maida 
et al., 2008; White et al., 2007). It is clear that further investigations are necessary to 
demonstrate the clinical feasibility of this pulmonary delivery of the anorectic gut 
secreted peptides, including a challenge concerning the relatively narrow therapeutic 
window of these peptides (Batterham et al., 2003; Degen et al., 2005; Sloth et al., 2007). 
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APPENDIX 1 
 
 
EXPERIMENTAL SETUP FOR STUDYING FOOD INTAKE 
SUPPRESSION FOLLOWING PULMONARY 
ADMINISTRATION OF ANORECTIC GUT SECRETED 
PEPTIDES 
 
 
 This appendix detailed the experimental setup to establish 1) the housing and 
acclimatization of animals (rats) to demonstrate physiological food and water intake and 
body weight gain and 2) the pulmonary administration operation minimally affecting 
such physiological values. This setup was used in the studies of PYY and OXM, as 
described in Chapters 3 through 5.  
 Animals were housed individually in metabolic cages throughout acclimatization 
and subsequent study periods. As shown in Figure A1.1, in each cage, animals were 
allowed to have free access to food pellet and bottle water, while excreted urine and feces 
were separated to the bottom of the cage to avoid their re-intake. The cage rack was 
placed in the Room B27 of the Smith Building in the AAALAC-accredited animal care 
and housing facility at VCU. This facility was tightly controlled with respect to 
temperature at 20-23 oC, relative humidity at 40-70 % and dark-light cycling of 12-12 h 
(i.e., between 6 pm and 6 am). While the animal care facility was generally maintained 
by dedicated VCU personnel, animals used in this study were accessed only by the 
investigators, due to a need of monitoring food and water intake and body weight. On 
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each day, animals were given pre-weighed food and water by the investigators, and their 
intake was determined by weight difference. Food spills were also recovered from the 
cage as much as possible.  
                               
Figure A1.1 Individual animal housing in the metabolic cage system with free access to 
pre-weighed food pellets and bottled water. 
 
 
 Pulmonary administration was carried out by two methods, intra- and oro-tracheal 
solution instillation. Animals were transferred from the care facility to the laboratory 
(Smith Room 422) and first anesthetized with isoflurane vapors in a chamber box. The 
chamber box was placed in the chemical hood to avoid possible exposure to the 
investigators (Figure A1.2 shows it outside the hood for the purpose of demonstration). 
Isoflurane vapors were maintained at 4 % (v/v), generated from an Ohmeda Tech 4 
Surgivet® vaporizer (Smiths Medical North America, Waukesha, WN) in a carrier gas of 
95 % oxygen and 5 % air at a flow rate of 3.5 L/min. Typically, sufficient depth of the 
anesthesia was achieved within 4 min, confirmed by the loss of corneal and pedal 
reflexes. 
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Figure A1.2 Isoflurane anesthetic system for pulmonary administration in rats. The 
chamber box (shown on the left) was placed inside the chemical hood 
during the experiment; it is shown outside for the purpose of 
demonstration.  
 
 
Following confirmation of adequate anesthesia, animals were placed in a supine 
position on a surgical board. For intratracheal instillation, the board was inclined at 30o 
from the horizontal, and the animal was suspended with the upper jaw on a stainless steel 
rod, attached on the surgical board, as shown in Figure A1.3 (A). Throughout the 
procedure, animals received supplemental anesthesia through nose only exposure to the 
isoflurane vapors. The tracheal region was surgically exposed, and a small incision was 
made between the 4th and 5th cartilaginous rings. Then, 60 µl of dosing solution prepared 
freshly prior to experiments was directly instilled into the lung by a 1 ml insulin syringe 
(Becton Dickinson, Franklin Lakes,  NJ) by projecting the needle tip just before the 
tracheal bifurcation. Immediately, the incision was carefully sealed with the Nexaband® 
surgical glue (Webster Veterinary Supply, Inc., Sterling, MA). The animal was held in a 
vertical position for 1 min to minimize the cough reflexes before returning to the cage. 
For orotracheal instillation, the board was inclined at 60ο from the horizontal, and the 
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animal was suspended with the upper jaw on the steel rod, as shown in Figure A1.3 (B). 
Using a small animal fiber-optic laryngoscope (LS-1; PennCentury, Inc., Philadelphia, 
PA), an opening of the tracheal lumen was visually confirmed through the oral cavity, 
and 100 µl of dosing solution prepared freshly prior to experiments was directly instilled 
into the lung through a 8.5 cm PEEK extension tubing (O.D. 0.01 mm; Upchurch 
Scientific, Oak Harbor, WA) attached to a 1 ml insulin syringe. This tubing was custom-
equipped with a ball-tip at 3 cm from its tip, so that it could be inserted in the tracheal 
lumen until its tip was positioned just before the tracheal bifurcation. The animal was 
then held in a vertical position for 1 min to minimize the cough reflexes and returned to 
the cage for recovery from the anesthesia (typically within 4 min). Animals did not show 
any abnormal signs such as cough reflexes, abnormal breathing and nasal secretion. In 
Chapter 5, this intratracheal instillation was also carried out, yet under the pentobarbital 
anesthesia due to a need of multiple blood samplings during the study period. 
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Figure A1.3 Operational photographs of A) intratracheal and B) orotracheal solution 
instillation in rats under the isoflurane anesthesia. 
A) B) 
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APPENDIX 2 
 
 
VALIDATION OF c-FOS AND NPY SPECIFIC 
IMMUNOFLUORESCENCE DETECTION  
 
 
 Immunofluorescence staining potentially involves false positive signal as a result 
of non-specific binding of antibodies, despite targeting specific protein binding. Hence, to 
ensure that the results shown in Chapters 3 and 4 were indeed from specific binding to c-
Fos and NPY, it was important to validate a lack of non-specific binding detection. 
Accordingly, the brain hypothalamus ARC sections were prepared from untreated rats, 
and the immunofluorescent staining protocol was then followed, as described in 
Chapter 3, yet omitting the use of 1) both primary and secondary antibodies or 2) primary 
antibody only, and otherwise, 3) replacing the primary antibody with rabbit serum.  
 Figure A2.1 shows the immunofluorescence micrographs for these validation 
controls, confirming the absence of fluorescence signals in all cases and thus, non-
specific binding as well as autofluorescence from the tissues. This in turn verified that the 
positive signals shown in Chapters 3 and 4 resulted from specific binding of c-Fos and 
NPY in each brain location.  
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Figure A2.1 Immunofluorescence micrographs of the right hypothalamus ARC region of the rat brain sections, prepared by omitting 
the use of 1) both primary and secondary antibodies or 2) primary antibody only, and otherwise, 3) by replacing the 
primary antibody with rabbit serum in the protocol for A) c-Fos and B) NPY staining used in Chapters 3 and 4. The 
c-Fos and NPY micrograph images were taken under the 400X and 100X magnification, respectively; the scale bars 
represent 50 µm. 
2) Without primary 
antibody 
3) Replacing primary 
antibody with rabbit serum 
A)  
B)  
1) Without primary 
and secondary 
antibodies 
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APPENDIX 3 
 
PYY ENZYME IMMUNOASSAY PROCEDURE 
 
 
         This appendix describes the standard operating procedure of the Millipore total 
PYY enzyme immunoassay for the analysis of rat plasma. This was used in Chapter 5 for 
PYY3-36 concentration determination in rat plasma for pharmacokinetic assessments. The 
procedure was carried out in the following order: 
1) Bring all assay components to room temperature before use. 
2) Add 20 µl of the proprietary assay buffer, 20 µl of the PYY standards or plasma 
samples and then 20 µl of the proprietary blocking solution to each well. 
3) Incubate at room temperature for 30 min on the microplate shaker at 400–500 rpm; 
the plate should be sealed. 
4) Add 50 µl of the 1:1 mixture of the capture and detection antibodies to each well, 
followed by 90 min incubation at room temperature on the microplate shaker at 400-
500 rpm; the plate should be sealed. 
5) Wash the wells 6 times with 300 µl of the proprietary washing buffer using  
automatic plate washer (Wellwash 4MK2, Labsystems, Finland). The washing buffer 
was prepared by mixing 100 ml of the buffer concentrate with 900 ml of distilled 
water.  
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6) Add 100 µl of the SA-HRP enzyme solution to each well, followed by incubation for 
30 min on the microplate shaker at 400-500 rpm; the plate should be sealed. 
7) Wash the wells 6 times with 300 µl of the washing buffer. 
8) Add 100 µl of the substrate solution to each well, followed by incubation for 30 min 
on the microplate shaker at 400-500 rpm; the plate should be sealed. This operation 
generates blue color proportional to PYY concentration. 
9) Add 100 µl of the stop solution (0.3 M HCl) to each well and shake the plate for ~30 
sec at 200 rpm to ensure sufficient mixing. 
10)  Read the optical density (OD) at 450 nm using a microplate reader (Precision  
Microplate Reader EmaxTM, Molecular Devices Corporation, Sunnyvale, CA) within 
5 min; the OD values at 590 nm was also measured for the background correction. 
11)  Construct the calibration curve by plotting the OD values against the         
logarithmic PYY concentrations (0.1, 0.2, 0.5, 0.8, 1, 1.5, 2.0 and 4.0 ng/ml) of the 
standards on a semi-log scale and fitting to the following four parameter log-logistic 
equation: 
       Y = [A – D] / [1 + (log X/log C) ^ B] + D   
 where X and Y are the PYY concentration and OD value, respectively; A and D are 
the maximum and minimum OD values, respectively; B and C are the Hill slope and 
the half maximal reactive PYY concentration, respectively. 
12) Using the calibration equation, back calculate PYY concentrations in rat plasma 
samples. 
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APPENDIX 4 
 
 
LUNG KINETIC MODELING ANALYSIS OF IN VIVO 
DATA BY CURVE-FITTING USING SCIENTIST® 
 
 
In Chapter 5, the plasma concentration versus time profile data for different 4-
6 kDa peptides following pulmonary administration in rats were analyzed using the 
nonlinear curve-fitting program, Scientist®. This appendix outlines the Scientist®, model 
program and curve-fitting procedure in more detail using the data for PYY3-36 following 
pulmonary administration, as an example. 
The lung kinetic model was assumed, incorporating two-compartment systemic 
disposition kinetics, as described in Figure 5.2. This model was fitted to the plasma 
concentration-time profile data for each peptide using the Scientist®. This software 
required three different electronic files for curve-fitting: Model File (*.EQN), Data File 
(*.MMD), and Parameter File (*.PAR). Generally, the curve-fitting was carried out as 
follows: 
1) According to the kinetic model described in Figure 5.2, differential equations were  
programmed alongside initial conditions, e.g., Figure A4.1(A).  
2) Following compilation, the plasma concentration versus time data were filled in a data  
    file, e.g., Figure A4.1(B). 
3) A parameter file contained the initial estimates for ka and knal and the systemic    
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    disposition parameters, i.e., k12, k21, kE, Vcc and Vpc, the latter being fixed with the     
values derived from the intravenous injection profile through the curve-stripping    
method; the dose, D was also fixed, e.g., Figure A4.1(C). 
4) Nonlinear regression was performed using the Simplex mode, followed by the modified 
Gauss-Newton regression. 
5) Plot and statistical outputs ensured the successful curve-fitting, e.g., Figures A4.2 and  
   A4.3, respectively, assessed by the visual inspection and the goodness-of-fit statistical 
parameters. The coefficient of determination (COD) and the model selection criteria 
(MSC) were calculated as follows: 
  COD = ∑ wi . (Yobs,i-Yobs,mean)2 -∑ wi . (Yobs,i–Ycal,i)2  
                     ∑ wi . (Yobs,i-Yobs,mean)2 
                                                                                
where wi is the weight applied to each data point, Yobs,i and Ycal,i are the observed and the 
model predicted values, respectively; Yobs,mean is the weighted mean of the observed data. 
A COD value of 1 would indicate that the model exactly matches the data. 
MSC = ln [ ∑ wi . (Yobs,i-Yobs,mean)2 ] – 2p/n 
            ∑ wi . (Yobs,i-Ycal,i)2 
 
where p and n are the number of parameters and data points, respectively.  
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A)  
// In vivo Pulmonary Kinetic Disposition Model  
// ka = first-order pulmonary absorption rate constant 
// knal = first-order non-absorptive loss rate constant 
// L = lung compartment 
// C = central compartment 
// P = peripheral compartment 
// 
IndVars: T 
DepVars: CC 
Params: ka, k12, k21, ke, Vcc, knal, D, Vpc 
ML'=-(ka+knal)*ML 
MC'= ka*ML-(k12+ ke)*MC+ k21*MP 
MP'= k12*MC- k21*MP 
CC=MC/Vcc 
CP=MP/ Vpc 
 
*** 
// Initial conditions 
T=0 
ML=D 
MC=0 
MP=0 
 
 
C) 
Fix Param Name Lower Limit Value Upper Limit 
 ka -infinity 0.015 infinity 
 k12 -infinity 0.023 infinity 
 k21 -infinity 0.090 infinity 
 kE -infinity 0.030 infinity 
 VCC -infinity 27.680 infinity 
 knal -infinity 0.200 infinity 
 D -infinity 24000.000 infinity 
 VPC  -infinity 5.920 infinity 
 
Figure A4.1 Representative A) model file, B) data file and C) parameter file of the 
Scientist® for curve-fitting the averaged plasma concentration-time profiles 
of peptides following intratracheal instillation in rats. The values in B) and 
C) are the plasma concentration-time data and the initial or fixed parameter 
estimates for PYY3-36 at 0.08 mg/kg, respectively.  
 
T CC 
0   0.00 
5 62.08 
10 74.95 
20 65.68 
30 47.91 
45 33.89 
60 14.20 
90 10.05 
B) 
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Figure A4.2 Plasma PYY concentration-time profile plots and their curve-fitting, 
generated by the Scientist® for PYY3-36, following intratracheal 
instillation at 0.08 mg/kg. The solid curve represents the model 
predicted profile, generated by the software. 
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Figure A4.3 Statistical output file generated by the Scientist® as a result of nonlinear 
curve-fitting of the mean plasma concentration-time data for PYY3-36 
following pulmonary administration at 0.08 mg/kg. 
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APPENDIX 5 
 
 
ORIGINAL DATA SHEETS 
 
 
TABLE OF CONTENTS 
CHAPTER 3 
Table A5.1-A5.6  Cumulative food intake and daily water intake and body weight 
gain in rats following: 
Table A5.1.  Single pulmonary administration of saline by intratracheal 
instillation. 
Table A5.2. # 1  Single pulmonary administration of PYY3-36 at 0.08 mg/kg by 
intratracheal instillation. 
   Table A5.3. # 2  Single pulmonary administration of PYY3-36 at 0.40 mg/kg by 
intratracheal instillation. 
 Table A5.4. # 3  Single pulmonary administration of PYY3-36 at 0.80 mg/kg by 
intratracheal instillation. 
Table A5.5. # 4 Single pulmonary administration of PYY1-36 at 0.90 mg/kg in rats 
by intratracheal instillation. 
    Table A5.6. # 5   Single pulmonary administration of PYY13-36 at 0.60 mg/kg in rats 
by intratracheal instillation. 
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Table A5.7 c-Fos pixel count in the bilateral hypothalamus arcuate nucleus 
region at 4 h following single pulmonary administration of saline 
and PYY in rats by intratracheal instillation. 
Table A5.8-A5.10   Cumulative food and water intake and body weight gain in rats   
during and following: 
Table A5.8 # 6    Repeated daily pulmonary administration of saline for 7 days by 
orotracheal instillation. 
Table A5.9 # 7        Repeated daily pulmonary administration of PYY3-36 at 0.08 mg/kg 
for 7 days by orotracheal instillation. 
Table A5.10 # 8   Repeated daily pulmonary administration of PYY3-36 at 0.80 mg/kg 
for 7 days by orotracheal instillation. 
Table A5.11-A5.13  Daily food and water intake and body weight gain in rats during 
and following: 
Table A5.11 # 9   Repeated daily pulmonary administration of saline for 7 days by 
orotracheal instillation. 
Table A5.12 # 10    Repeated daily pulmonary administration of PYY3-36 at 0.08 mg/kg 
for 7 days by orotracheal instillation. 
Table A5.13 # 11    Repeated daily pulmonary administration of PYY3-36 at 0.80 mg/kg 
for 7 days by orotracheal instillation. 
Table A5.14 Dark-phase food intake during repeated daily pulmonary 
administration of saline, PYY3-36 at 0.08 and 0.80 mg/kg for 7 days 
in rats by orotracheal instillation. 
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CHAPTER 4 
Table A5.15-A5.20 Cumulative food intake and daily water intake and body weight 
gain in rats following: 
Table A5.15  Single pulmonary administration of saline by orotracheal 
instillation. 
Table A5.16 # 12 Single pulmonary administration of OXM1-37 at 0.05 mg/kg by 
orotracheal instillation. 
Table A5.17 # 13 Single pulmonary administration of OXM1-37 at 0.20 mg/kg by 
orotracheal instillation. 
Table A5.18 # 14 Single pulmonary administration of OXM1-37 at 0.50 mg/kg by 
orotracheal instillation. 
Table A5.19 # 15 Single pulmonary administration of OXM30-37 at 0.10 mg/kg by 
orotracheal instillation. 
Table A5.20 # 16 Single pulmonary administration of NAc-OXM30-37 at 0.10 mg/kg 
by orotracheal instillation. 
Table A5.21 c-Fos pixel count in the bilateral hypothalamus arcuate nucleus and 
paraventricular nucleus regions and in the unilateral brainstem area 
postrema region at 4 h following single pulmonary administration 
of saline and OXM1-37 at 0.50 mg/kg in rats by orotracheal 
instillation. 
Table A5.22-A5.23 Cumulative food and water intake and body weight gain in rats 
during and following: 
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Table A5.22 #17 Repeated daily pulmonary administration of OXM1-37 at 0.50 
mg/kg for 7 days by orotracheal instillation. 
Table A5.23 #18 Repeated daily pulmonary administration of OXM1-37 at 0.50 
mg/kg for 7 days by orotracheal instillation. 
Table A5.24 Dark-phase food intake during repeated daily pulmonary 
administration of saline and OXM1-37 at 0.50 mg/kg for 7 days by 
orotracheal instillation. 
CHAPTER 5 
Table A5.25 PYY3-36 concentration in plasma following single intravenous 
injection of 0.08 mg/kg in rats.  
Table A5.26 PYY3-36 concentration in plasma following single pulmonary 
administration by intratracheal instillation of 0.08 mg/kg in rats.  
Table A5.27 PYY3-36 concentration in plasma following single pulmonary 
administration by intratracheal instillation of 0.80 mg/kg in rats. 
Table A5.28 Noncompartmental pharmacokinetic parameters for intravenous 
injection of PYY3-36 at 0.08 mg/kg in rats. 
Table A5.29 Noncompartmental pharmacokinetic parameters for intratracheal 
instillation of PYY3-36 at 0.08 mg/kg in rats. 
Table A5.30 Noncompartmental pharmacokinetic parameters for intratracheal 
instillation of PYY3-36 at 0.80 mg/kg in rats. 
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Table A5.31 Exenatide concentration in plasma following single intravenous 
injection of 0.60 mg/kg in rats; the data extracted from Gedulin et al., 
2008. 
Table A5.32 Exenatide concentration in plasma following single pulmonary 
administration by intratracheal instillation of 0.60 mg/kg in rats; the 
data extracted from Gedulin et al., 2008. 
Table A5.33 Insulin concentration in plasma following single intravenous injection 
of 0.003 mg/kg in rats; in-house unpublished data. 
Table A5.34 Insulin concentration in plasma following single pulmonary 
administration by intratracheal instillation of 0.03 mg/kg in rats; in-
house unpublished data. 
Table A5.35 PTH1-34 concentration in plasma following single intravenous injection 
of 0.08 mg/kg in rats; the data extracted from Patton et al., 1994. 
Table A5.36 PTH1-34 concentration in plasma following single pulmonary 
administration by intratracheal instillation of 0.30 mg/kg in rats; the 
data extracted from Patton et al., 1994. 
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